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Abstract 
 
Epigenetic and transcriptional control of the microglial inflammatory response: potential 
insights into neuro-inflammaging 
 
by 
 
Sandra E Muroy 
 
Doctor of Philosophy in Molecular and Cell Biology 
 
University of California, Berkeley 
 
Professor Kaoru Saijo, Chair 
 
 
Inflammation is an evolutionarily conserved host defense response during infection or 
injury that seeks to remove the causal agent that led to its initiation, repair the damaged 
tissue(s) and restore homeostasis. Thus, transient inflammation in response to an 
adequate threat with a quick return to a basal resting state is beneficial. However, when 
inflammation becomes inappropriately increased or prolonged it can have severe 
pathophysiological consequences.  
During aging, the immune system shifts to a proinflammatory state characterized 
by low-grade, chronic, sterile inflammation that has been termed ‘inflammaging’. The 
proinflammatory state largely results from chronic activation of the innate immune 
system and includes elevated circulating levels of inflammatory mediators including the 
immune cell signaling molecules (cytokines) Interleukin (IL)-1, IL-6, IL-8, IL-13, IL-18, 
tumor necrosis factor (TNFα) and antivirals (the type I interferons (IFN-I). Numerous 
factors are thought to contribute to inflammaging and amongst potential mechanisms 
high fat feeding/obesity and associated increases in gut permeability to bacterial 
endotoxins, as well as, cellular senescence have emerged as key contributors. 
Importantly, inflammaging is tightly correlated to global indicators of poor health status, 
multimorbidity, impairment in day-to-day living activities and is thought to underlie or 
accelerate most age-dependent chronic diseases (e.g. cardiovascular disease, diabetes, 
cancer, as well as, neurodegenerative conditions like Parkinson’s disease (PD) and 
Alzheimer’s disease (AD)). 
While mechanisms driving peripheral inflammaging are beginning to be 
understood, the etiology of neuro-inflammaging is a crucially unresolved issue. An 
important source of inflammation in the brain are the non-neuronal cell populations (glia) 
which provide structural, trophic, and other physiological support for neurons, and 
especially, the activity of microglia–the brain’s own resident innate immune cells. 
Microglia are essential for brain development, maintenance and protection throughout 
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the life of an organism. As innate immune cells, however, they can also mount a full 
inflammatory response to infection or environmental challenge to restore brain health. 
Environmental factors, for example, changes in peripheral levels of fatty acids, 
bacterial endotoxins or proinflammatory mediators resulting from high fat feeding or gut 
permeabilization can cause microglia to undergo changes that signal activation. Most 
importantly, microglia lose their homeostatic function during aging, becoming less 
neuroprotective and increasingly neurotoxic. Microglia-mediated inflammation, for 
example, is strongly linked to age-induced cognitive impairment, is a common hallmark 
of both PD and AD, and is believed to be mechanistically important in driving 
pathogenesis. Thus, there is great interest in discovering factors that regulate age-
related changes in microglial inflammatory function. 
Although inflammation is a complex and multicomponent response, a key point of 
its control occurs at the level of gene transcription and involves several classes of 
transcription factors, transcriptional co-regulators and chromatin modifications. A recent 
2017 study by Soreq et al., identified a relatively unknown gene, PHD finger protein 15 
(PHF15) as one of the top 25 differentially expressed genes in microglia during non-
pathological aging in humans, with PHF15 levels increasing with age. Sequence and 
structural similarity to other members of the PHF family suggest that PHF15 might 
function as a putative chromatin-mediated gene regulator.  
I first sought to determine whether PHF15 could repress inflammatory function in 
microglia. If so, I wanted to investigate whether factors known to be causal in 
inflammaging (e.g. high fat feeding/obesity or cellular senescence) lead to age-
dependent cognitive impairment via modulation of microglial PHF15. A major hallmark 
of senescent cells is the secretion of inflammatory mediators including various cytokines 
(lL-6, IL-1β, IL-8), chemoattractant cytokines (chemokines; for example C-X-C motif 
chemokine 10 (CXCL10), C-C motif chemokine ligand (CCL-) 5 (CCL5) and CCL20), 
antivirals (IFN-I), growth factors and extracellular matrix proteases termed the 
senescence-associated secretory phenotype (SASP). Secretion of the SASP is partially 
controlled by the Cyclic GMP-AMP (cGAMP) synthase (cGAS)-Stimulator of interferon 
genes (STING) (cGAS-STING) cytosolic DNA sensing pathway at the molecular level. 
Thus, peripheral changes induced by high fat feeding/obesity or the SASP could lead to 
increased neuroinflammation via inhibition of microglial PHF15. 
I show that Phf15 significantly represses proinflammatory gene expression in 
mouse microglia, modulating both the magnitude and duration of the inflammatory 
response. Importantly, Phf15 regulates both basal expression and signal-dependent 
upregulation of proinflammatory genes—which constitute different phases of the 
transcriptional inflammatory response and are controlled by distinct molecular 
mechanisms. Global transcriptional changes after Phf15 knockout in a microglial cell 
line further revealed that Phf15 may specifically regulate the antiviral response, as well 
as, proinflammatory factor production and secretion. Interestingly, loss of Phf15 resulted 
in increased IFN-I-dependent and inflammatory gene expression profiles that closely 
mimic transcriptional changes in aged microglia. Together, my data indicate that Phf15 
is an important novel repressor of microglial inflammatory function which might 
counteract age-induced inflammation in the healthy, aging brain. 
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Interestingly, I found decreased expression levels of Il-6, a key proinflammatory 
cytokine expressed by senescent cells in the hippocampus–an area which mediates 
various memory-related process–of aged (27-month old) STING-deficient mice. 
However, this decrease did not translate to improved working memory or differences in 
Phf15 mRNA expression in the brain, suggesting that expression of SASP-related 
inflammatory factors by the cGAS-STING pathway does not proceed via inhibition of 
Phf15. Similarly, prolonged treatment with a high fat diet/obesity did not affect working 
memory or levels of Phf15 in the mouse brain, suggesting that brain inflammation 
resulting from a HFD or obesity is likewise not a result of Phf15 downregulation. 
Overall, my results suggest that Phf15 could function as an immune regulatory 
checkpoint, restraining the transition from a homeostatic phenotype towards the chronic, 
proinflammatory, IFN-I responsive state seen in microglia in the aged brain. Further 
understanding of its exact mechanism of action could lend insight into possible future 
therapeutic intervention. 
 
  i 
Dedication 
 
In pursuit of higher education, a journey that took much longer than I imagined 
when I first set out, I have been separated from my family and those important to me, 
twice now. Each time with uncertainty and sadness as to when I might be able to see 
them again. I wish to dedicate this to them and to my friends and allies on this journey. 
 
To Maya and Valentina, my two bright little stars. You will shine with your own light. 
To my best friend, my sine qua non (without which it could not be) Dushka Hernández 
who has been there with me through everything. Every step of the way. 
To my brother from another mother, Matthew Goff, thank you for letting me be a part of 
the pack and taking care of my 3 girls. 
To my parents, Elvira and Rafael Muroy, who never gave up. In anything. 
To my brother, Rafael Muroy, I hope to one day be as helpful and reliable as you. 
To my sister, Romy Muroy, you’ve had your own tough struggle and are coming out on 
top. 
To my aunts, Makío, Mamali, Matami, Muy and Tía Juany, thank you for being my 
second mothers. 
To my grandmother Tita, you were denied an education past elementary school but 
made absolutely sure that your daughters were able to have it. 
To my dear friend Jane Reynolds, thank you for being a part of my family and for 
making us feel safe and loved. 
To my friend and mentor, Daniela Kaufer, you are such a source of comfort and joy. 
To my current mentor, Kaoru Saijo, this would absolutely not have been possible 
without you. 
To my allies, Abby Rincón, Oscar Dubón, Liliana Iglesias, Meng So, Father Rigo 
Calocarivas and the Multicultural Institute, thank you for having my back. 
To my UndocuGrads, not explicitly named to protect their identities, thank you for 
walking this road by my side. 
And to all those who face the fight in pursuit of the dream of higher education 
 
This is for you. 
 
 
 
 
 
 
 
 
 
  ii 
Table of Contents 
CHAPTER 1: INTRODUCTION ........................................................................................ 1 
SECTION 1.1: THE INFLAMMATORY RESPONSE ................................................................... 1 
SECTION 1.2: AGING AND INFLAMMATION ........................................................................... 1 
SECTION 1.3: CAUSES OF INFLAMMAGING .......................................................................... 2 
High fat feeding and obesity ...................................................................................... 2 
Cellular senescence .................................................................................................. 3 
SECTION 1.4: THE ROLE OF MICROGLIA ............................................................................. 4 
SECTION 1.5: TRANSCRIPTIONAL CONTROL OF THE MICROGLIAL INFLAMMATORY RESPONSE .. 5 
CHAPTER 2: PHF15—A NOVEL TRANSCRIPTIONAL REPRESSOR REGULATING 
REGULATING INFLAMMATION IN MOUSE MICROGLIA ............................................. 7 
SECTION 2.1: ABSTRACT .................................................................................................. 7 
SECTION 2.2: INTRODUCTION ........................................................................................... 8 
SECTION 2.3: RESULTS .................................................................................................... 9 
SECTION 2.4: DISCUSSION ............................................................................................. 20 
SECTION 2.5: MATERIALS AND METHODS ........................................................................ 23 
SECTION 2.6: SUPPLEMENTARY MATERIALS .................................................................... 26 
Supplementary Figures 2.1-2.9 and Supplementary Table 2.1. .............................. 26 
CHAPTER 3: LOSS OF STING FUNCTION INHIBITS AGE-RELATED INCREASE IN 
INCREASE IN IL-6 EXPRESSION BUT DOES NOT IMPROVE MOTOR AND 
AND MEMORY FUNCTION IN AGED MICE ................................................................. 39 
SECTION 3.1: RATIONALE ............................................................................................... 39 
SECTION 3.2: RESULTS .................................................................................................. 39 
SECTION 3.3: DISCUSSION ............................................................................................. 50 
SECTION 3.4: MATERIALS AND METHODS ........................................................................ 52 
CHAPTER 4: PROLONGED HIGH FAT FEEDING AND OBESITY DO NOT AFFECT 
AFFECT WORKING MEMORY OR LEVELS OF PHF15 IN THE MOUSE BRAIN ...... 55 
SECTION 4.1: RATIONALE ............................................................................................... 55 
SECTION 4.2: RESULTS .................................................................................................. 55 
SECTION 4.3: DISCUSSION ............................................................................................. 60 
SECTION 4.4: MATERIALS AND METHODS ........................................................................ 61 
CHAPTER 5: CLOSING REMARKS.............................................................................. 64 
REFERENCES ............................................................................................................... 66 
 
 
 
 
 
 
 
 
 
  iii 
Acknowledgements 
 
This work was supported by the Berkeley Fellowship for Graduate Study. I would like to 
thank Hector Nolla and Alma Valeros of the Cancer Research Laboratory (LSA Flow 
Cytometry Facility) for their kind assistance with cell sorting and the UC Berkeley Office 
of Laboratory Animal Care for animal husbandry support. 
  1 
 
Chapter 1: Introduction 
 
Section 1.1: The inflammatory response 
 
Inflammation is an evolutionarily selected defense response of body tissues to harmful 
stimuli such as infection, injury or damaged cells produced by acute cellular stress 1. It 
consists of a complex biological response that involves, at its core, cells of the innate 
immune system–largely macrophages, monocytes, neutrophils and dendritic cells–the 
vasculature, and various molecular mediators, for example, cytokines and chemokines 
which mediate immune cell communication and chemotaxis, respectively. The function 
of inflammation is to remove the causal agent that led to its initiation, clear out damaged 
cells and initiate repair of the wounded tissue(s) 2. Inflammation thus has a beneficial 
role in health when it is transiently activated, that is, when the inflammatory response is 
activated quickly in response to adequate threat and resolves to a basal resting state in 
a timely fashion. However, when inflammation becomes excessive, inappropriate or 
sustained, it can lead to severe pathophysiological consequences. 
 
 
Section 1.2: Aging and inflammation 
 
Aging is associated with immune dysregulation which is characterized by high 
circulating levels of proinflammatory mediators in the absence of adequate immune 
triggers, as well as, a decreased capacity to effectively mount an inflammatory response 
when faced with pathogenic and noxious immune challenge 3,4 . The proinflammatory 
state results largely from a chronic activation of the innate immune system and includes 
elevated circulating levels of inflammatory mediators including the cytokines Interleukin 
(IL)-1, IL-1 receptor antagonist protein (IL-1RN), IL-6, IL-8, IL-18, tumor necrosis factor 
(TNFα) and its receptors (TNF receptor superfamily members 1A and 1B), antivirals (the 
type I interferons (IFN-I) including IFNα and IFNβ), transforming growth factor β (TGFβ) 
and serum amyloid A (SSA) 2. This state of sterile, chronic, low-grade inflammation has 
been termed ‘inflammaging’ 3 and contributes to the pathogenesis of many age-
dependent chronic diseases including diabetes, cardiovascular disease, cancer, 
osteoporosis, depression, as well as, neurodegenerative conditions like Parkinson’s 
disease (PD), Alzheimer’s disease (AD) and dementia 2,5–10. It is also tightly correlated 
to global indicators of poor health status, for example, multimorbidity, disability in day-to-
day living activities, frailty, and premature death 2,11–13. 
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Section 1.3: Causes of inflammaging 
 
Numerous factors are thought to contribute to inflammaging and potential mechanisms 
include genetic predisposition, cellular senescence, obesity, increased gut permeability, 
dysbiosis (changes in composition of the host microbiota), mitochondrial dysfunction, 
defects in autophagy, immune cell dysregulation, and chronic infections (for review see 
2). 
 
High fat feeding and obesity 
 
One of the most pathologically relevant mechanisms due to its high and increasing 
prevalence is diet-induced obesity (DIO) 14. DIO generally results from ingestion of a 
calorically-rich and high fat diet (HFD) 15 resulting in significantly increased body weight, 
chronic, low-grade systemic inflammation 16–18, metabolic impairment 18 and cognitive 
deficits 19,20. Increased dietary fatty acid (FA) intake, for example, induces immune 
activation and inflammatory responses in many metabolic organs including adipose 
tissue, pancreas, liver, muscle, and brain 18,21. FA’s can directly stimulate immune cells 
and adipocytes by binding to specialized receptors (i.e., Toll-like receptor 4 (TLR4), a 
sensor for pathogen detection) 22,23 and activate transcription factors like Nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB) and Activator Protein 1 (AP-1), 
which upregulate expression of proinflammatory cytokines (e.g. IL-1β, TNFα and IL-6) 
and other proinflammatory mediators. 
Importantly, consumption of a HFD can also lead to increased gut permeability, 
increasing the concentration of bacterial products, like the endotoxin lipopolysaccharide 
(LPS), a component of gram-negative bacterial cell walls, in the bloodstream. For 
example, the HFD itself can aid in solubilizing bacterial products easing their transport 
into systemic circulation 24–26. Furthermore, HFD consumption leads to changes in the 
composition of gut microbiota populations. Reductions of beneficial commensal 
microbes which control the growth of pathogenic commensals and maintain intestinal 
barrier integrity via production of mucus and metabolites 27,28 leads to dysbiosis as well 
as permeabilization of the gut barrier 29 allowing passage of bacterial endotoxins into 
circulation. Increased levels of LPS in the bloodstream, for example, can then activate 
inflammatory responses in immune and other cells via direct binding to TLR4.  
In the brain, DIO can lead to changes in blood brain barrier (BBB) permeability 
which can alter brain homeostasis by allowing entry of substances (including 
pathogens) normally restricted to peripheral circulation. For example, mice fed a HFD 
(60% kcal from fat) for 14 weeks showed decreased protein levels of tight and adherens 
junction proteins claudin-5 and occludin 30. Similarly, 16 weeks of HFD treatment (60% 
kcal from fat) led to increased Evans Blue dye extravasation, a functional measure of 
BBB permeability, into the central nervous system (CNS) in mice 31. Importantly, chronic 
inflammation resulting from DIO was specifically identified as being linked to impaired 
cognitive function 32. For example, in humans, obesity is associated with 
neuroinflammation and architectural changes in grey and white matter 33–36 Similarly, 
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increased plasma levels of Il-6 and C-reactive protein (CRP), which are markers of 
peripheral inflammation, were associated with changes in brain morphology, e.g. 
decreased hippocampal volume and cortical surface area, as well as, impaired learning 
and memory 37. In rodents, a HFD (60% kcal from fat) administered for 20-21 weeks, 
resulted in deterioration of spatial memory and spatial learning, measured using 
behavioral assays such as the Y-maze 38, Morris water maze 39,40 and the T-maze 41. 
These changes were accompanied by increased levels of Tnfα, Il-6, the 
chemoattractant cytokine (chemokine) Ccl2 and Nitric oxide synthase, inducible (Nos2, 
which synthesizes the reactive nitrogen species NO), as well as, non-neuronal brain cell 
(glial cell) activation. 
In addition to its direct contribution to systemic inflammation, DIO can lead to 
further metabolic dysfunction and accumulated evidence shows that consuming a HFD 
induces a low grade but sustained inflammation in macrophages that triggers insulin 
resistance and is important for the pathogenesis of Type 2 diabetes mellitus (T2DM) 
17,18,42. Importantly, T2DM is associated with cognitive impairment 43,44 and alongside 
aging, is one of the most critical risk factors for neurodegenerative diseases such as AD 
45, which is characterized by progressive cognitive decline and brain inflammation 46,47 
(among other hallmarks). 
  
Cellular senescence 
 
A second mechanisms posited to underlie inflammaging that is gaining strong traction is 
cellular senescence 48, which is characterized by terminal cell cycle arrest of aged or 
damaged cells 49,50. Senescent cells display phenotypic changes resulting from altered 
metabolism, organization of chromatin and transcriptional activity 51. A major hallmark of 
senescent cells is the secretion of inflammatory mediators including various cytokines 
(IL-6, IL-1β, IL-8), chemokines (e.g. CCL5, CCL20, CXCL10), antivirals (IFN-I), growth 
factors and extracellular matrix proteases termed the senescence-associated secretory 
phenotype (SASP) 51,52. The SASP is thought to have evolved as a way for senescent 
cells to communicate with the immune system in order to drive senescent cell clearance 
and activate tissue repair via stimulation of progenitor cells 53. However, chronic 
exposure to the inflammatory response driven by the SASP is thought to underlie many 
of the senescence-associated adverse effects on aging-dependent diseases 54,55. 
Through the SASP, senescent cells can also transmit senescence to neighboring cells 
in a paracrine fashion 51. 
At the molecular level, an important regulator of SASP gene expression is the 
Cyclic GMP-AMP (cGAMP) synthase (cGAS)-Stimulator of interferon genes (STING) 
(cGAS-STING) cytosolic DNA sensing pathway 56. cGAS-STING is part of the innate 
immune pattern recognition receptor network and its central function is the secretion of 
inflammatory and antiviral cytokines and chemokines in response to infection 57,58. 
However, the cGAS-STING pathway can also sense endogenous DNA ligands, for 
example, cytosolic DNA fragments resulting from aging or other stress-induced damage 
that can trigger its activation 51,59. 
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Recent studies suggest that senescent cells are detectable in the brain, with 
senescence likely occurring in glial cells (astrocytes, microglia, oligodendrocytes) which 
are replication-competent 60,61. Glial cells, especially microglia and astrocytes, normally 
provide metabolic, trophic and structural support to neurons but could contribute to 
sustained neuroinflammatory and neurodegenerative processes via secretion of SASP-
related factors including proinflammatory cytokines and matrix metalloproteinases 
(MMPs) which disrupt cell-cell contacts necessary for structural and functional neuronal-
glial and inter-glial interactions that maintain metabolic and ion homeostasis in neurons 
62,63. In the aged brain, chronic inflammation is associated with pathological cellular and 
tissue changes, for example significant decreases in certain neuronal populations, 
axonal and dendritic arborizations, number of dendritic spines, synapses and brain 
volume 64 which result in cognitive impairment, memory loss and loss of motor 
coordination. 
 
 
Section 1.4: The role of microglia 
 
While the mechanisms driving peripheral inflammaging are beginning to be understood, 
the etiology of neuro-inflammaging is a critically unresolved issue. As previously 
mentioned, an important source of neuroinflammation in the aging brain are the 
replication-competent glia and especially the activity of microglia, the brain’s own 
specialized resident innate immune cells. Microglia are essential for brain development, 
protection, maintenance and repair and throughout the life of an organism, carry out a 
number of routine functions necessary for brain homeostasis including shaping of 
neuronal circuitry, synaptic pruning, production of trophic factors, and removal of debris 
and dead cells 65–69. As immune cells, however, microglia are also capable of mounting 
a full inflammatory response to infection or environmental challenge 67,70–73. Microglia 
express pattern recognition receptors including TLRs to sense environmental changes, 
such as invasion by pathogens or neuronal damage, and respond by releasing 
proinflammatory mediators to clear threats and restore brain health 71,73,74. 
Environmental factors, for example, changes in peripheral levels of FAs, LPS and 
cytokines resulting from high fat feeding or gut permeabilization can cause microglia to 
undergo changes that signal activation, leading to increased expression of 
proinflammatory factors and reactive oxygen species (ROS) 75 that can damage the 
surrounding healthy tissue 76. For example, studies in the mouse microglial cell line BV-
2 showed that FA-activated BV-2 cell culture medium was cytotoxic to neurons 77.  
Most importantly, microglia lose their homeostatic function during aging and 
adopt a proinflammatory phenotype, becoming prone to dysfunctional reactions 78. 
This microglial aging phenotype is complex, characterized by impairment of their 
neuroprotective functions and at the same time, increases in their neurotoxic responses 
79,80. For example, aged microglia upregulate specific markers associated with 
increased antigen presentation 81,82, lysosomal functioning 83,84, and pathogen 
recognition (including TLR expression) 85 and increase production and release of 
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proinflammatory cytokines 86–89, changes which are associated with immune reactivity. 
At the same time, aged microglia become less competent to respond efficiently to 
immune challenge 90,91. 
 Importantly, microglial inflammatory activation has been strongly linked to both 
cognitive deficits and neurodegenerative diseases 79. Microglia-mediated 
neuroinflammation, for example, is a common hallmark of both Parkinson’s disease and 
Alzheimer’s disease and is believed to be mechanistically important in driving 
pathogenesis 92–96. 
 
 
Section 1.5: Transcriptional control of the microglial inflammatory response 
 
Due to their central role in mediating neuroinflammatory processes and their 
contribution to the pathophysiology of neurodegenerative diseases, there is great 
interest in discovering factors that regulate age-related changes in microglial function, 
specifically, repressors of microglial inflammatory output. Although the inflammatory 
response is a complex and multicomponent process, a crucial control point occurs at the 
level of gene transcription, and is regulated by several classes of transcription factors, 
transcriptional co-regulators and chromatin modifications (for review see 97–99). 
A recent study by Soreq et al., 100 which compared transcriptional profiles of 
different brain cell types and regions throughout healthy human aging found microglial 
gene expression profiles as being one of the most predictive markers of biological age in 
the brain. The same study identified a relatively unknown gene, PHD finger protein 15 
(PHF15) among the top 25 differentially expressed genes in microglia during non-
pathological aging, with PHF15 levels increasing with age. I hypothesized that PHF15 
might function as a chromatin-mediated gene regulator based on several lines of 
evidence. First, PHF15 (JADE2) is a member of the PHF/JADE family of proteins, which 
includes PHF17 (JADE1) and PHF16 (JADE3) paralogs. All 3 JADE family proteins bear 
two mid-molecule PHD-finger domains 101 a motif commonly found in transcriptional co-
activators and chromatin remodeling factors (e.g. Autoimmune regulator, AIRE; EP300 
or E1A binding protein p300, p300; Creb-binding protein, CBP; and Polycomb-like 
protein, PCL) 102–105. Second, a study by Han et al., 106 found that PHF15 associates 
with Lysine-specific demethylase 1 (LSD1), a key demethylase of histone 3 lysine 4 107 
in mouse embryonic stem cells. LSD1 is a member of the CoREST co-repressor 
complex (a chromatin remodeling complex) 106,108,109 and is required for transcriptional 
repression of inflammation in microglia 110. Third, PHF15 and other PHF family proteins 
have also been found as members of the Human acetylase binding to ORC1 (HBO1) 
histone acetyltransferase complex 111,112 –a chromatin modifying complex. An additional 
member of the HBO1 complex, Inhibitor of growth 4 (ING4) has been shown to 
negatively regulate the transcription factor NF-κB in immune precursor cells, tying HBO1 
complex function to negative regulation of inflammatory signaling 113. Fourth, PHF17 
(JADE1) is a known epigenetic regulator 101 and structural and sequence similarity 
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between PHF17 and PHF15 led me to believe that this might be the case for PHF15 as 
well. 
Based on its putative function as a chromatin-mediated gene regulator, I sought 
to determine whether PHF15 might regulate inflammation in microglia, and specifically, 
whether it might repress aging-related inflammatory gene expression. Given that PHF15 
expression levels increased in the healthy, aging human brain 100, putatively it might 
function as a transcriptional repressor helping to counteract the age-dependent 
microglial inflammatory phenotype. If so, I hypothesized that factors thought to be 
causal in inflammaging and linked to cognitive dysfunction might affect brain function via 
modulation of microglial PHF15. For example, prolonged consumption of a HFD or 
obesity might lead to decreased levels of PHF15 and increased microglial inflammatory 
output leading to neuroinflammation and cognitive deficits. Similarly, factors involved in 
mediating SASP-related inflammatory gene expression, i.e., the cGAS-STING pathway 
might regulate expression of the SASP via interactions with PHF15.. 
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Chapter 2: Phf15—a novel transcriptional repressor regulating inflammation in 
mouse microglia 
 
Copyright notice 
Portions of the following chapter were reprinted with permission from “Phf15—a novel 
transcriptional repressor regulating inflammation in mouse microglia” Muroy SE, 
Timblin GA, Preininger MK, Cedillo P and Saijo K (2019) bioRxiv 
doi: https://doi.org/10.1101/2019.12.17.879940. © 2019 The Authors. Used under a 
CC-BY-ND 4.0 International license (https://creativecommons.org/licenses/by-nd/4.0/). 
The text was modified from the original by presenting the Results section (Section 2.3) 
before the Materials and Methods (Section 2.5) and removing the Declarations section. 
Additionally, Supplementary Figures 2.10 and 2.11 were not included as part of the 
original text and are referred to in Section 2.4: Discussion. 
 
Section 2.1: Abstract  
 
Aim: Excessive microglial inflammation has emerged as a key player in mediating the 
effects of aging and neurodegeneration on brain dysfunction. Thus, there is great 
interest in discovering transcriptional repressors that can control this process. We aimed 
to examine whether PHF15— one of the top differentially expressed genes in microglia 
during aging in humans—could regulate transcription of proinflammatory mediators in 
microglia. 
 
Methods: RT-qPCR was used to assess Phf15 mRNA expression in mouse brain 
during aging. Loss-of-function (shRNA-mediated knockdown (KD) and CRISPR/Cas9-
mediated knockout (KO) of Phf15) and gain-of-function (retroviral overexpression (OE) 
of murine Phf15 cDNA) studies in a murine microglial cell line (SIM-A9) followed by 
immune activation with lipopolysaccharide (LPS) were used to determine the effect of 
Phf15 on proinflammatory factor (Tnfα, Il-1β, Nos2) mRNA expression. RNA-
sequencing was used to determine global transcriptional changes after Phf15 knockout 
under basal conditions and after LPS stimulation. 
 
Results: Phf15 expression increases in mouse brain during aging, similar to humans. 
KD, KO and OE studies determined that Phf15 represses mRNA expression levels of 
proinflammatory mediators such as Tnfα, Il-1β and Nos2. Global transcriptional 
changes after Phf15 KO showed that Phf15 specifically represses genes related to the 
antiviral (type I interferon) response and cytokine production in microglia. 
 
Conclusion: We provide the first evidence that Phf15 is an important transcriptional 
repressor of microglial inflammation, regulating the antiviral response and 
proinflammatory cytokine production. Importantly, Phf15 regulates both basal and 
signal-dependent activation and controls the magnitude and duration of the microglial 
inflammatory response. 
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Keywords: Phf15, microglia, transcriptional repression, neuroinflammation. 
Section 2.2: Introduction 
 
Microglia are the resident myeloid-lineage cells of the brain. They actively provide 
homeostatic surveillance of the brain parenchyma playing critical roles during 
development, maintenance and repair throughout the life of an organism. As innate 
immune cells, however, microglia are also capable of mounting a full inflammatory 
response to environmental challenge in order to clear threats and restore homeostasis 
65,67,70–73. Microglia express pattern recognition receptors including Toll-like receptors 
(TLRs) to sense changes in their environment, such as infection by pathogens or 
endogenous danger signals. They can then respond by releasing proinflammatory 
mediators such as Tumor necrosis factor alpha (TNFα), Interleukin 1 beta (IL-1β), 
Interleukin 6 (IL-6), reactive oxygen species (ROS) and reactive nitrogen species (RNS) 
including nitric oxide (NO) to protect against threats 71,73,74. 
Although beneficial when their production is tightly controlled, deregulated or 
sustained microglial production of inflammatory mediators can lead to collateral damage 
of surrounding neurons and other cells 73,74,110. Thus, the transition to an activated state, 
as well as, timely resolution of the inflammatory response, must be tightly regulated. 
Increasing evidence suggests that during aging, microglia lose homeostatic function and 
acquire a proinflammatory phenotype that exacerbates aging-related brain dysfunction 8. 
Indeed, aberrant microglia activation has been found in many types of age-related 
neurodegenerative conditions for example, Parkinson’s disease (PD) and Alzheimer’s 
disease (AD) which are marked by inflammatory processes involving glia, and microglia 
in particular 8,114,115. 
 Since excessive production of proinflammatory mediators is neurotoxic 110,116–118, 
various molecular mechanisms exist to regulate transcriptional repression of 
inflammatory gene expression. For example, basal state repression, that is, before the 
arrival of an activating signal, is generally carried out via recruitment of co-repressor 
complexes that prevent initiation of inflammatory gene transcription. After stimulation by 
an activating signal, additional mechanisms can maintain quiescence by restraining 
active transcription. Finally, numerous mechanisms mediate the timely resolution of the 
inflammatory response at the transcriptional level, including transrepression 
mechanisms that can remove transcription factors from inflammatory gene promoters 
97–99,110,119. 
Studies have also highlighted an important role for chromatin modifications in the 
transcriptional control of inflammatory gene expression 120,121. A recent study by Soreq 
et al., 100 which compared transcriptional profiles of different brain cell types and regions 
throughout healthy human aging found microglial gene expression profiles as being one 
of the most predictive markers of biological age in the brain. The same study identified a 
relatively unknown gene, PHD finger protein 15 (PHF15) among the top 25 differentially 
expressed genes in microglia during aging. Work in embryonic stem cells, and 
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sequence and structural similarity to other members of the PHF family, indicate that 
PHF15 is a putative chromatin-mediated gene regulator 106. 
Given that aging skews microglia towards a proinflammatory phenotype, and that 
PHF15 was found to be highly upregulated during non-pathological aging, we sought to 
determine whether Phf15 might regulate microglial inflammatory function. We found that 
Phf15 strongly represses proinflammatory gene expression, regulating both basal and 
signal-dependent activation and modulating the magnitude and duration of the mouse 
microglial inflammatory response. Importantly, Phf15 seems to regulate proinflammatory 
and Interferon type I (IFN-I)-dependent gene expression. Increased IFN-I tone and 
proinflammatory cytokine expression are both hallmarks of the aging brain 122–125. Our 
findings suggest that Phf15 is an important novel repressor of microglial inflammatory 
function that might work to counteract age-induced inflammation in the healthy, aging 
brain. 
 
 
Section 2.3: Results 
 
Aging increases Phf15 expression in mouse brain.  
To investigate whether Phf15 increases in mouse brains similar to humans 100, we 
measured Phf15 mRNA expression in mouse frontal cortical brain areas across age. We 
were interested in frontal cortical regions because of their involvement in mediating 
various aspects of cognitive function and because they are selectively affected in 
several aging-related neurodegenerative conditions like PD, AD and frontotemporal 
dementia (FTD) 126,127.  
 
Figure 2.1. Phf15 expression increases in aged mouse frontal cortical areas.  Phf15 
expression was significantly elevated in frontal cortical areas of old (~20-month-old; red bar) 
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mice compared to young (~2.5 month old; black bar) mice. Data are mean ± SEM (n = 4 
young, n = 5 middle aged, n = 12 old). One-way ANOVA with Tukey’s post hoc 
comparisons between age groups: **p<0.01. 
 
We found that compared to young (~2.5-month-old) mice, old (~20-month-old) 
mice had significantly elevated Phf15 mRNA levels in frontal cortical areas (Figure 2.1). 
Middle-aged (~14-month-old) mice showed a trend towards increased Phf15 mRNA 
expression that did not reach statistical significance. Our data suggest that Phf15 
expression increases in mouse frontal cortical regions upon normal aging, similar to 
what was previously reported in humans 100. 
 
Knockdown of Phf15 increases the magnitude of the microglial inflammatory 
response.  
 
To determine whether Phf15 regulates microglial inflammatory function, we performed 
loss-of function studies via shRNA-mediated knockdown (KD) in a murine microglial cell 
line, SIM-A9, followed by immune activation with lipopolysaccharide (LPS), a 
component of gram-negative bacterial cell walls and Toll-like receptor 4 (TLR4) agonist. 
We chose LPS because 1) Intraperitoneal and/or intracranial administration of LPS in 
mice led to increased microglial activation, neuroinflammation, neuronal loss including 
loss of dopaminergic neurons in the substantia nigra in a mouse model of PD 110, as 
well as, cognitive and neurological deficits 128, 2) Aged individuals show increased 
systemic levels of LPS in the bloodstream 129 which are associated with increased 
inflammation and microglial activation 130 and 3) In humans, TLR4 activation is linked to 
age-related pathologies like PD and AD 131–133. Thus, LPS serves as a relevant aging-
related physiological immune stimulant. 
KD of Phf15 resulted in a significant reduction in Phf15 mRNA transcript levels of 
52% or 60% for cell lines shPhf15-1 or shPhf15-2, respectively (Figure 2.2A), as well as, 
significantly increased mRNA expression of Tnfα, a proinflammatory cytokine, after KD 
with shPhf15-2 at 0, 1, 6 and 12 hours after LPS stimulation (Figure 2.2B). Similarly, 
mRNA levels of Nos2, the enzyme that catalyzes the production of NO, were 
significantly elevated at 1, 6 and 12 hours post stimulation for shPhf15-2 and 0, 6 and 
12 hours for shPhf15-1 (Figure 2.2D). Overall, our experiments show that ~50-60% KD, 
the equivalent of a “heterozygous” condition, results in increased expression of 
proinflammatory mediators over a 12 hour time course that resolves and falls below 
control levels by 24 hours after immune stimulation. Importantly, microglial inflammatory 
function was elevated in the absence of immune stimulation (0 hour time point, Figures 
2.2B, D and No stimulation condition, Figures 2.2C, E), suggesting a loss of repressive 
mechanisms that inhibit basal state inflammatory gene transcription. 
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Figure 2.2. Knockdown of Phf15 increases the magnitude of the microglial 
response. (A) Knockdown efficiency for anti-Phf15 shRNAs shPhf15-1 (blue bar, 52% 
knockdown) and shPhf15-2 (red bar, 60% knockdown) Data are mean ± SEM (n = 3 per 
condition). Unpaired t-tests between shPhf15-1 or shPhf15-2 and shCtrl (control scrambled 
shRNA) cells: asterisks indicate **p<0.01. 24-hour time course experiments showing 
relative mRNA expression levels of Tnfα (B) and Nos2 (D) after LPS stimulation of shRNAs 
shPhf15-1 and shPhf15-2 compared to shCtrl. “No stimulation” 0 hr time point is shown for 
Tnfα (C) and Nos2 (E). Data are mean ± SEM (n = 3 per condition). Unpaired t-tests for 
shPhf15-1 or shPhf15-2 and shCtrl cells for individual timepoints: asterisks indicate 
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*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
LPS, lipopolysaccharide; Tnfα, Tumor necrosis factor alpha; Nos2, Nitric oxide synthase, 
inducible. 
 
We repeated the immune activation time course experiments in Phf15 KD cells 
using two separate immune stimulants specific to two distinct TLRs to test the pathway 
specificity of the inflammatory response. CpG Oligodeoxynucleotide (CpG ODN), a 
synthetic bacterial and viral DNA mimic targets TLR9 and Polyinosinic:polycytidylic acid 
(Poly(I:C)), a synthetic viral dsRNA mimic targets TLR3. Although TLR4 uses both the 
Myeloid differentiation primary response 88 (MyD88) and TIR-domain-containing 
adapter-inducing interferon-β (TRIF) downstream adapters to transduce its inflammatory 
cascade, TLR9 and TLR3 utilize MyD88 or TRIF respectively (Supplementary Figure 
2.1) 134,135. 
Immune stimulation with CpG ODN and Poly(I:C) both yielded similar results to 
those obtained with LPS stimulation (Supplementary Figures 2.2 and 2.3, respectively) 
denoting no adapter selectivity and confirming that Phf15 antagonizes inflammatory 
gene expression downstream of both the MyD88 and TRIF signaling pathways. 
 
Genetic deletion of Phf15 increases the magnitude and prolongs the duration of 
the microglial inflammatory response.  
 
Since our KD strategy resulted in ~50% reduction in Phf15 mRNA expression, we next 
performed CRISPR/Cas9-mediated genetic deletion of Phf15 in SIM-A9 microglial cells 
followed by immune activation with LPS. Knockout (KO) of Phf15 (Figure 2.3A) resulted 
in significantly increased LPS-induced expression of Tnfα (Figure 2.3B), Il-1β (Figure 
2.3D) and Nos2, albeit to a lesser extent (Figure 2.3F) over a 24-hour time course. 
Importantly, mRNA levels of both Tnfα and Il-1β remained elevated at 24 hours 
compared to control cells, denoting a prolonged inflammatory response and failure to 
return to steady-state. mRNA expression of Nos2 showed a significant upregulation 
over 12 hours (0, 1 and 12 hour timepoints) but had returned to control levels by 24 
hours (Figure 2.3F). Notably, basal expression of all 3 genes was significantly elevated, 
with a 4-fold increase in Tnfα, 14-fold increase in Il-1β and 32-fold increase in Nos2 
when comparing KO versus control cells Figures 2.3C, E, G).  
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Figure 2.3. Knockout of Phf15 increases the magnitude and duration of inflammatory 
expression. (A) Percent reduction in Phf15 transcript expression in Phf15 knockout SIM-
microglia (Phf15 KO, red bar) compared to control (Ctrl, open bar). 24-hour time course 
experiments showing relative mRNA expression levels of Tnfα (B), Il-1β (D), and Nos2 (F) 
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after LPS stimulation. No stimulation (0 hr time point or baseline) expression of Tnfα (C), Il-
1β (E) and Nos2 (G) are also shown. All data are mean ± SEM (n = 3 per condition). 
Unpaired t-tests between Phf15 KO and control cells for percent reduction and for individual 
timepoints: asterisks indicate *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
LPS, lipopolysaccharide; Tnfα, Tumor necrosis factor alpha; Il-1β, Interleukin 1 beta; Nos2, 
Nitric oxide synthase, inducible. 
 
Time course experiments after stimulation of TLR9 with CpG-ODN 
(Supplementary Figure 2.4) and TLR3 with Poly(I:C) (Supplementary Figure 2.5) in 
Phf15 KO cells again yielded similar results to LPS stimulation in Phf15 KO microglial 
cells, denoting no difference in downstream adapter selectivity and confirming our prior 
KD results. 
Overall, KO of Phf15 resulted in a more severe phenotype compared to our KD 
results, increasing the magnitude and prolonging the duration of the microglial 
inflammatory response. Taken together, our KD and KO results indicate that Phf15 
functions to restrict microglial inflammatory output, regulating the magnitude and 
duration, as well as, basal inhibition of the inflammatory response.  
 
Overexpression of Phf15 in microglia results in a dampened inflammatory 
response 
 
To further test the role of Phf15 as a repressor of proinflammatory genes, we carried out 
gain-of-function studies of Phf15 in SIM-A9 cells. Overexpression (OE) via retroviral 
delivery of the full-length murine Phf15 cDNA (Figure 2.4A) resulted in significantly 
decreased expression of Tnfα at 6 hours (Figure 2.4B), Il-1β (0, 6, 12 hours; Figure 
2.4D) and Nos2 (0, 6, 24 hours; Figure 2.4F). Notably, basal levels of both Il-1β and 
Nos2 were also significantly decreased (Figures 2.4E, G). Time course experiments 
following stimulation with CpG-ODN (Supplementary Figure 2.6) and Poly(I:C) 
(Supplementary Figure 2.7) likewise yielded similar results as LPS stimulation of Phf15 
OE microglia, displaying no adapter selectivity. 
Taken together, our OE results show a dampened microglial inflammatory 
response, revealing a reciprocal response phenotype compared to our KD and KO 
experiments. Collectively these results confirm that Phf15 functions to repress both 
basal and stimulus-dependent inflammatory gene expressions in microglia.  
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Figure 2.4. Phf15 overexpression decreases the microglial inflammatory response. 
overexpression (OE) of Phf15 in SIM-A9 microglia (red bar) versus control cells (Ctrl, open 
bar).  24-hour time course experiments showing relative mRNA expression levels of Tnfα 
(B), Il-1β (D), and Nos2 (F) after LPS stimulation. Baseline (0 hour time point, No 
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stimulation) expression of Tnfα (C), Il-1β (E), and Nos2 (G) are displayed separately from 
time course experiments. All data are mean ± SEM (n = 3 per condition). Unpaired t-tests 
between Phf15 OE and control cells for fold-overexpression and for individual time points: 
asterisks indicate *p<0.05, **p<0.01. 
LPS, lipopolysaccharide; Tnfα, Tumor necrosis factor alpha; Il-1β, Interleukin 1 beta; Nos2, 
Nitric oxide synthase, inducible. 
 
 
Loss of Phf15 affects global expression of genes involved in antiviral responses 
and regulation of inflammatory processes 
 
To examine global transcriptional changes as a result of Phf15 deletion in microglia, we 
carried out RNA-sequencing (RNA-seq) on Phf15 KO SIM-A9 cells under no stimulation 
conditions and 6 hours post LPS stimulation. We chose to examine the no stimulation 
condition (0 hour time point) based on our KD and KO time course results which 
showed that baseline is one of the most consistently and strongly deregulated time 
points. Importantly, elevated or ‘leaky’ proinflammatory mediator expression at baseline 
might result in chronic inflammation leading to neurodegeneration. Similarly, 6 hours 
after LPS stimulation corresponded to the peak of the transcriptional inflammatory 
response, with large increases in magnitude for both Il-1β and Nos2. 
Differential gene expression analysis revealed that 466 genes with log2 fold 
change > 1.5 and p adj < 0.01 were up-regulated and 309 genes with log2 fold change < 
-1.5 and p adj < 0.05 were downregulated (Figure 2.5A). Biological theme enrichment 
analysis using Metascape 136 on the upregulated genes revealed that the most enriched 
biological process categories under basal conditions were “response to virus” and 
“cytokine production” (Figure 2.5B, C). Under the “response to virus” category, there 
was significant upregulation of various interferon-stimulated genes (ISGs), for example 
Ifit1, Ifit3, Irf7, Isg15, Oas2 and Oasl2 (Figure 2.5C). The downregulated genes show 
more variability in the types of pathways affected, largely involving growth, 
differentiation and glial cell migration processes (Figure 2.5A and Supplementary Figure 
2.8A). 
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Figure 2.5. Loss of Phf15 affects the expression of genes involved in viral 
response and regulation of inflammatory processes in the absence of immune 
stimulation 
(A) Volcano plot representing the RNA-seq results. Orange dots represent differentially 
expressed genes in Phf15 knockout microglia compared to control (upregulated genes 
at a cutoff of log2fold change > 1.5 and p adj  < 0.01; downregulated genes at a cutoff of 
log2fold change < -1.5 and p adj < 0.05). (B) GO analysis for significantly upregulated 
genes showing biological process categories related to “response to virus” and 
“inflammatory response”. (C) Upregulated genes associated with response to virus and 
inflammatory response in the No stimulation (baseline) condition. Relative FPKM values 
were obtained by normalizing FPKM values of Phf15 knockout SIM-A9 microglia to 
control FPKM values for each gene (n = 3 per condition). Statistics are by DESeq2: 
#p<0.0001. (D) Top 5 enriched transcription factor binding motifs for the set of 
upregulated genes in the No stimulation (baseline) condition. 
 
Motif analysis for transcription factor (TF) binding sites enriched in the promoters 
of the upregulated genes at baseline revealed consensus motifs for Interferon (IFN) 
stimulated response element (ISRE, IRF binding motif), and motifs for IFN response 
factor 3 (IRF3) and IRF8 in the top 5 best matches. Also enriched were Activator protein 
1 (AP-1) and Nuclear factor kappa-light-chain-enhancer of activated B cells p65 subunit 
(NF-κB-p65) motifs. Both can regulate expression of canonical proinflammatory 
cytokines such as TNFα and IL-1β 137,138 (Figure 2.5D). Motif enrichment for the set of 
downregulated genes revealed motifs for Twist-related protein 2 (Twist2) and basic 
helix–loop–helix (bHLH) MIST1(BHLHA15). Twist2 has been shown to mediate cytokine 
downregulation after chronic NOD2 (a bacterial peptidoglycan sensor) stimulation 139. 
MIST1 has been shown to induce and maintain secretory architecture in cells 
specialized for secretion 140 (Supplementary Figure 2.8B). 
 Differential gene expression analysis after 6 hours of LPS stimulation in KO 
versus control cells revealed 576 up-regulated genes (log2 fold change > 1.5 and p adj 
< 0.01) and 322 down-regulated genes (log2 fold change < -1.5 and p adj < 0.05) 
(Figure 2.6A). Interestingly, by 6 hours after LPS administration, some of the most 
enriched biological process categories in KO cells were related to “cytokine secretion” 
and “immunoregulatory interaction” (Figure 2.6B and C), denoting a strong increase in 
magnitude of expression of genes involved in regulating the secretion of 
proinflammatory mediators. The downregulated genes at 6 hours after LPS stimulation 
in KO cells relative to control again displayed more variability, but did show decreases 
in biological process categories related to “regulation of defense response” and 
“cytokine production”, indicating negative regulation of these processes in Phf15 KO 
cells compared to control (Supplementary Figure 2.9A). 
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Figure 2.6. Knockout of Phf15 affects the expression of genes involved in 
inflammatory factor secretion and immunoregulatory processes after LPS 
stimulation 
(A) Volcano plot representing the RNA-seq results. Orange dots represent differentially 
expressed genes in Phf15 knockout microglia 6 hours after LPS administration 
compared to control (upregulated genes at a cutoff of log2fold change > 1.5 and p adj < 
0.01; downregulated genes at a cutoff of log2fold change < -1.5 and p adj < 0.05). (B) 
GO analysis for upregulated genes shows biological process categories associated with 
cytokine secretion and immunoregulatory interaction. (C) Upregulated genes associated 
with cytokine secretion and immunoregulatory interaction biological process categories 
6 hours post LPS stimulation. Relative FPKM values were obtained by normalizing 
FPKM values of Phf15 knockout SIM-A9 microglia to control FPKM values for each 
gene (n = 3 wells per condition). Statistics are by DESeq2: **p<0.01, $p<0.001, 
#p<0.0001. (D) Transcription factor binding motifs for the set of upregulated genes 6 
hours after LPS stimulation are enriched for Activator protein 1 (AP-1). 
 
 Motif enrichment analysis for TF binding sites enriched in the promoters of 
upregulated genes at the 6-hour time point revealed consensus sequences for AP-1, a 
key regulator of microglia reactivity in inflammation 141 (Figure 2.6D). Motif enrichment 
for the set of downregulated genes revealed motifs for ISRE (IRF binding motif), IRF1 
and IRF3 (Supplementary Figure 2.9B), supporting the observation that there is a 
negative “regulation of defense response” by 6 hours post stimulation. It is interesting to 
note that a functional transition from cytokine production to cytokine secretion seems to 
occur in the 6 hour period after LPS activation. 
Taken together, our RNA-seq results confirm that Phf15 is a repressor of 
microglial inflammatory gene expression, regulating the antiviral response—specifically, 
IFN-I-dependent responses—as well as processes related to proinflammatory cytokine 
production and release. 
 
 
Section 2.4: Discussion 
 
Our results show that Phf15 inhibits microglial expression of proinflammatory mediators 
under basal and signal-dependent activation, regulating both the magnitude and 
duration of the inflammatory response. Genetic deletion of PhfF15 in a microglial cell 
line followed by stimulation with LPS led to an exaggerated proinflammatory response 
with increased production of Tnfα, Il-1β and Nos2 over a time course of 24 hours. 
Importantly, levels of proinflammatory factors remained elevated at 24 hours 
demonstrating a sustained and prolonged response. Consistent with our LPS 
stimulation of TLR4 results, similar results were obtained after TLR9 and TLR3 
activation confirming that Phf15 is a general negative regulator and controls both the 
MyD88 and TRIF downstream signal transduction pathways (Supplementary Figure 2.1). 
Overexpression of Phf15 showed a dampened microglial inflammatory response, 
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highlighting a reciprocal response phenotype that further supports our loss-of-function 
results. 
Prolonged inflammation can damage surrounding healthy tissue, eventually 
resulting in neuronal degeneration and loss, and negatively affecting brain function. For 
example, levels of TNFα are seen to rapidly rise in experimental models of PD and are 
highly toxic to dopaminergic neurons 117,118,142. Similarly, high levels of TNFα are a 
hallmark of PD in humans 143–145. Additionally, both TNFα and IL-1β are involved in 
maintaining proper synaptic plasticity at physiological levels 146,147 and overproduction of 
these cytokines can result in neuronal death via excitotoxicity and cognitive dysfunction 
148,149. 
Our studies further demonstrate that Phf15 can regulate both basal and signal-
dependent microglial inflammatory gene expression. KD and KO of Phf15 in microglial 
cell lines resulted in significantly increased levels of proinflammatory cytokine gene 
expression 1) without stimulation and 2) after immune activation, while OE had the 
reverse effect. The inflammatory response is a tightly controlled process in immune cells 
in order to protect against unintended damage to healthy tissue. Even in aged microglia, 
where production and secretion of proinflammatory mediators is generally increased, 
this process is dependent upon treatment with immune stimulants 8,87,150. Increased 
proinflammatory cytokine gene expression without stimulation denotes constitutive or 
‘leaky’ expression of inflammatory mediators, simulating a state of low-grade but 
constant activation. Similarly, hyperresponsiveness to immune stimuli combined with a 
lack of resolution of the inflammatory response can lead to a state of chronic 
inflammation. All three can trigger pathological chronic inflammation in the brain which is 
detrimental to brain function. 
Importantly, distinct molecular mechanisms regulate transcriptional control of 
different phases (‘modules’) of the inflammatory response and it is noteworthy that 
Phf15 might be involved in regulating several of these. Basal inflammatory function, for 
example, is generally regulated by co-repressors such as nuclear receptor co-repressor 
(NCOR), silencing mediator of retinoid and thyroid receptors (SMRT) and REST co-
repressor 1, (RCOR1 or CoREST) that block poised promoters from active transcription, 
preventing ‘leaky’ expression of primary response genes (e.g., TNFα, Type I IFNs, IL-1β, 
etc.) (for review see 97). Significantly increased inflammatory gene transcription under 
baseline conditions, as observed in our Phf15 KD and KO experiments, suggests a loss 
of this repressive mechanism. 
After stimulation by an activating signal, additional mechanisms can maintain 
quiescence by restraining active transcription. For example, nuclear receptors like 
peroxisome proliferator-activated receptor-γ (PPARγ), glucocorticoid receptor (GR) and 
liver X receptors (LXRs) can inhibit the signal-activated exchange of co-repressors for 
co-activators at poised promoters, inhibiting the initiation of transcription 97,98. Lastly, 
several mechanisms regulate resolution of inflammation at the transcriptional level, 
including transrepression mechanisms that can remove transcription factors like NF-κB, 
from inflammatory gene promoters, effectively blocking expression of secondary 
response genes, that is, genes which require chromatin-modification as well as protein 
synthesis for their induction (for example Nos2 and ISGs) 97,99,110. Timely resolution of 
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an inflammatory response is crucial in order to limit cellular and tissue damage caused 
by prolonged or chronic inflammation. Our results suggest that Phf15 may be involved in 
regulating all three of the abovementioned mechanisms. 
But how might Phf15 be involved in regulating transcriptional repression of the 
inflammatory response? PHF15 was first described in embryonic stem cells as an E3 
ligase that directly targets Lysine-specific demethylase 1 (LSD1, Kdm1a)—a key 
demethylase of histone 3 lysine 4—for degradation 106. LSD1 has been identified as a 
member of the CoREST co-repressor complex 108,151 which is required for transcriptional 
repression of inflammation in microglia 110. Additionally, our preliminary data showed 
that Lsd1 is a potent inhibitor of inflammatory responses in microglia: primary microglia 
from LSD1 knockout (KO) mice exhibited significantly increased expression of 
proinflammatory genes after immune stimulation (Supplementary Figure 2.10). We 
therefore initially hypothesized that increased levels of Phf15 upon aging might lead to 
decreased levels of LSD1 and increased microglial inflammatory output. Our results, 
however, demonstrate that Phf15 itself inhibits microglial inflammatory function, thus, its 
purported mechanism for inhibition is likely not via degradation of LSD1 (Supplementary 
Figure 2.11). 
 Interestingly, the global transcriptional changes caused by Phf15 deletion are 
highly similar to previously reported age-associated transcriptional changes in microglia 
8,152,153. In particular, a study by Deczkowska et al., 154 found “immune system process” 
and specifically “response to virus” among the most highly upregulated biological 
categories for differentially expressed genes in microglia of young (2-month old) versus 
aged (22-month old) mice, consistent with our results in Phf15 KO microglia. Notably, a 
study by Hammond et al., 153 which used single-cell RNAseq to look at microglia profiles 
throughout the mouse lifespan, found subpopulations in aged (P540) mouse brains 
which were largely 1) inflammatory, that is, they upregulated Il-1β, Tnfα and other 
cytokines or 2) IFN-I-responsive, upregulating ISGs, particularly Ifit3, Irf7, Isg15, Oasl2, 
Ifitm3, and Rtp4, compared to younger adult (P100) brains. Similarly, a recent study 
from the Tabula Muris Consortium 155 which produced a single-cell transcriptomic atlas 
of 23 tissues and organs across the Mus musculus life span, confirmed that microglia in 
the aged (P540 and P720) brain are enriched for IFN-I-responsive genes and 
upregulate a similar set of genes including Ifit3, Irf7, Isg15, Oasl2, Ifitm3, and Rtp4. The 
genes upregulated by the interferon-responsive microglia clusters in both these studies 
are highly similar to those upregulated in our Phf15 KO cells under basal conditions 
(see Figure 2.5A and C). Because ISGs can modulate inflammation 122 it is possible that 
interferon-responsive microglia could play a role in contributing to the inflammatory 
signature found in the aged brain. Interestingly, among the set of downregulated genes 
in Phf15 KO cells at baseline and 6 hours after LPS stimulation, is Myocyte Enhancer 
Factor 2C (Mef2C). MEF2C is an important checkpoint inhibitor that restrains microglial 
activation in response to proinflammatory insults and is lost in brain aging via IFN-I 
mediated downregulation 154,156. Thus, an increase in Phf15 expression in microglia 
during healthy aging could putatively work to counteract not only microglial activation but 
increased IFN-I in the aged brain as well. 
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Notably, a recent study by Readhead et al., 157 found that several virus species 
are commonly present in the aged human brain. Among them, human herpesvirus 6A 
and 7 (HHV-6A and HHV-7) were highly upregulated in the brain of AD patients and 
were found to modulate host genes associated with AD risk, for example, Amyloid 
precursor protein (APP) processing. APP is the precursor molecule whose proteolysis 
forms amyloid-β (Aβ) and formation of Aβ plaques has long been thought of as the 
driving force behind Alzheimer’s disease 158. Aβ has more recently been found to have 
antimicrobial properties, 159 conferring increased resistance against infection from both 
bacteria and viruses 160. App is among the significantly upregulated genes under basal 
conditions in our Phf15 KO cells (log2 fold change =1.492 and p adj < 0.0001; see 
Figure 2.5A). Upregulation of App due to loss of Phf15 in mouse microglia is thus 
consistent with our data showing Phf15 regulation of the antiviral microglial response. 
Altogether, our results show that Phf15 is a novel repressor of microglial 
inflammatory gene expression, regulating both the magnitude and time-to-resolution of 
the inflammatory response. Importantly, Phf15 also serves to repress baseline 
inflammatory output in the absence of immune activation. Putatively, increases in Phf15 
during healthy aging could help counteract brain inflammation and protect brain health. 
Future studies will determine the mechanism of action of Phf15. For example, the 
identity of its binding partner proteins, its genome-wide binding sites and associated 
histone marks to determine the specific gene regulatory regions it interacts with (e.g. 
active enhancers or promoters). Additionally, studies in Phf15 KO mice will elucidate 
whether loss of Phf15-mediated repression of pro-inflammatory factors is sufficient to 
induce cognitive decline or exacerbate LPS-induced neurotoxicity of dopaminergic 
neurons in the substantia nigra. 
 
 
Section 2.5: Materials and Methods 
 
Animals 
 
Adult male C57Bl6/J mice were purchased from The Jackson Laboratory and 
maintained on a 12:12-h light–dark cycle (lights on at 0700 hours) with ad libitum 
access to food and water and aged for ~2.5, ~14 or ~20 months. All animal care and 
procedures were approved by the University of California, Berkeley Animal Care and 
Use Committee. 
 
shRNA-mediated knockdown of Phf15 in murine microglial cells 
 
pGIPZ Lentiviral mouse Jade2 shRNA constructs or a control scrambled shRNA were 
purchased from Dharmacon (Lafayette, CO). Lentivirus was packaged via co-
transfection of each pGIPZ-shRNA with pCMV-VSV-G (Addgene plasmid #8454) 161 and 
pCMV-dR8.2 (Addgene plasmid #8455) 161 into HEK 293T cells using Lipofectamine 
3000 reagent (Life Technologies, Carlsbad, CA) according to the manufacturer’s 
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instructions. Viral supernatant was harvested after 48 hours and incubated with SIM-A9 
murine microglial cells in SIM-A9 complete medium (DMEM/F12, Life Technologies, 
Carlsbad, CA), 10% fetal bovine serum (FBS; GE Healthcare Life Sciences, Chicago, 
IL), 5% horse serum (HS; GE Healthcare Life Sciences, Chicago, IL), 1% Pen-Strep 
(Life Technologies, Carlsbad, CA)). After 48 hours, GFP+ cells were sorted by FACS on 
an Aria Fusion (BD Biosciences, San Jose, CA; UC Berkeley Cancer Research 
Laboratory), expanded and subcultured for immune stimulation experiments. Percent 
knockdown was determined via RT-qPCR. 
 
Overexpression of Phf15 in murine microglial cells 
 
A Phf15 overexpression vector was constructed by cloning the full length Phf15 cDNA 
(Mus musculus PHD finger protein 15, mRNA cDNA clone MGC:143877 
IMAGE:40094330) obtained from Dharmacon (Lafayette, CO) into a pMYs-IRES-GFP 
retroviral vector (Cell Biolabs Inc, San Diego, CA). Virus expressing the full length Phf15 
cDNA or empty vector control were co-transfected with pCL-10 A1 (Addgene plasmid 
#15805) 162 in HEK293T cells using Lipofectamine 3000 (Life Technologies, Carlsbad, 
CA) reagent according to the manufacturer’s instructions. SIM-A9 cells were incubated 
with virus for 24 hrs and then sorted via FACS on an Aria Fusion, expanded and 
subcultured for immune stimulation experiments. Fold overexpression was verified via 
RT-qPCR. 
 
Generation of Phf15 knockout microglia 
 
Phf15 knockout (KO) SIM-A9 cells were generated using the Alt-R CRISPR-Cas9–
mediated gene editing system (guide RNA sequence 
ACTACATCCTGGCGGACCCGTGG) from IDT (Coralville, IA) using CRISPRMAX 
Lipofectamine reagent (IDT) as per the manufacturer’s instructions. ATTO 550+ cells 
were single-cell sorted on an Aria Fusion. Clones were screened for Phf15 deletion 
using PCR (primers Forward: agcacacttgtaaccctcct and Reverse: gaccaatgtctgttgttgttcg) 
followed by restriction digest with BtgI (New England Biolabs, Ipswich, MA). Percent 
decrease in Phf15 mRNA transcript expression was determined via RT-qPCR (primer 
sequences are listed in Supplementary Table 2.1). 
 
Immune stimulation 
 
For all immune stimulation time course experiments, cells (knockdown, knockout, 
overexpression and respective controls) were subcultured in 24-well plates at a density 
of 105 cells/well (in triplicate) and stimulated with LPS (final concentration of 100 ng/ml; 
Sigma Aldrich, St. Louis, MO), CpG ODN (final concentration of 2.5 uM; InvivoGen, San 
Diego, CA) or Poly(I:C) (final concentration of 25 uM; Sigma Aldrich, St. Louis, MO) for 1, 
6, 12 or 24 hrs. No stimulation controls received an equivalent volume of sterile 1xPBS 
(Invitrogen, Carlsbad, CA). 
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RNA extraction 
 
Mice were sacrificed according to the approved protocol. Brains were quickly isolated 
and frontal cortical areas were dissected, flash frozen and stored at − 80 °C. RNA was 
extracted using a bead homogenizer (30 seconds, setting ‘5’’; Bead Mill, VWR) in Trizol 
reagent (ThermoFisher, Waltham, MA). Total RNA was extracted using the Direct-zol 
RNA miniprep kit (Zymo Research, Irvine, CA) according to the manufacturer’s 
instructions. For cell lines, after immune stimulation, media was aspirated and wells 
were washed 2x with ice-cold 1xPBS (Invitrogen, Carlsbad, CA). RNA was extracted 
using the Direct-zol RNA miniprep kit (Zymo Research, Irvine, CA). 
 
Real-Time Quantitative PCR (RT-qPCR)  
 
cDNA was reversed transcribed from total RNA using the SuperScript™ III First-Strand 
Synthesis System kit (ThermoFisher, Waltham, MA) following the manufacturer’s 
instructions. RT-qPCR was run using SYBR green (Roche, Pleasanton, CA) on a 
QuantStudio 6 (ThermoFisher, Waltham, MA) real-time PCR machine. All RT-qPCR 
primers were specific to the desired template, spanned exon-exon junctions and 
captured all transcript variants for the specific gene under study. Ct values were 
normalized to the housekeeping gene Hprt. Primer sequences used in this study are 
listed in Supplementary Table 2.1. 
RNA-seq library preparation and analysis 
RNA was extracted from a total of n= 3 replicates per condition (Phf15 KO or control) 
and was used to prepare libraries for RNA sequencing using the KAPA mRNA 
HyperPrep Kit according to the manufacturer’s instructions (KAPA Biosystems, 
Wilmington, MA). Libraries were quality control checked via Qubit (ThermoFisher, 
Waltham, MA) and via RT-qPCR with a next generation sequencing (NGS) library 
quantification kit (Zymo Research, Irvine, CA). RNA sequencing (1 lane) was performed 
on a HiSeq4000 sequencing system (Illumina Inc., San Diego, CA; UC Berkeley 
Genomics Sequencing Laboratory). Sequencing reads were aligned to the Mus 
musculus reference genome assembly GRCm38 (mm10) using Spliced Transcripts 
Alignment to a Reference (STAR) aligner 163. Count data was analyzed with 
Hypergeometric Optimization of Motif EnRichment (HOMER) software for next-
generation sequencing analysis (http://homer.ucsd.edu/homer/ngs/index.html) which 
uses the R/Bioconductor package DESeq2 164 to perform differential gene expression 
analysis. To adjust for multiple comparisons, DESeq2 uses the Benjamini-Hochberg 
procedure to control the false discovery rate (FDR) and returned FDR adjusted p values 
and log2fold expression changes between Phf15 KO and control conditions for each 
gene. Genes were filtered by adjusted p value (adjusted p < 0.01 for upregulated genes 
or 0.05 for downregulated genes) and log2 fold change in expression (greater than 1.5 
log2fold change for upregulated genes and less than -1.5 for downregulated genes). 
Too few downregulated genes (< 200) passed the more stringent adjusted p < 0.01 
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cutoff for robust downstream biological function analysis, so the adjusted p value 
threshold was lowered to p adj < 0.05. Results were visualized using the R package 
EnhancedVolcano 165. Lists of upregulated and downregulated genes were input into 
Metascape 136, a gene annotation and analysis tool, to determine enriched biological 
themes within the gene lists. 
Motif enrichment 
 
Transcription factor binding sites (motifs) were analyzed using HOMER 
(http://homer.ucsd.edu/homer/ngs/index.html). 
 
Statistical Analysis 
 
Relative mRNA expression of Phf15 in mouse frontal cortical areas was analyzed using 
ordinary one-way ANOVA with post hoc Tukey’s multiple comparisons to compare 
expression levels across age. Percent knockdown and time course experiments 
measuring expression levels of inflammatory markers (Tnfα, Nos2, Il-1β) between 
control and Phf15 shRNAs shPhf15-1 and shPhf15-2 after immune stimulation (with 
LPS, CpG-ODN or Poly(I:C)) were analyzed via Unpaired t-tests between each shRNA 
versus control shRNA within timepoint. Fold overexpression or percent reduction and 
time course experiments for Phf15 overexpression and knockout cell lines were 
analyzed using Unpaired t-tests (overexpression or knockout vs. respective control) 
within each time point. P < 0.05 was considered significant in all experiments. 
 
Section 2.6: Supplementary Materials 
 
Supplementary Figures 2.1-2.9 and Supplementary Table 2.1. 
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Supplementary Figure 2.1. Schematic of TLR4, TLR9 and TLR3 signal transduction 
pathways. TLR4, activated by LPS, uses both the MyD88 and TRIF downstream adapters 
to transduce its signaling cascade, leading to transcription of canonical proinflammatory 
factors like TNFα, IL-1β and Nos2 as well as, the type I interferons (IFNs). TLR9, activated 
by CpG ODN, uses the MyD88 adapter, while TLR3, stimulated here by Poly(I:C), uses 
TRIF. 
TLR4, Toll-like receptor 4; LPS, lipopolysaccharide; MyD88, Myeloid differentiation primary 
response 88; TRIF, TIR-domain-containing adapter-inducing interferon-β; TLR9, Toll-like 
receptor 9; CpG ODN, CpG Oligodeoxynucleotide; TLR3, Toll-like receptor 3; Poly(I:C), 
Polyinosinic:polycytidylic acid; AP-1, Activator protein 1; NF-κB, Nuclear factor kappa-light-
chain-enhancer of activated B cells; TNFα, tumor necrosis factor alpha; IL-1β, Interleukin 1 
beta; Nos2, Nitric oxide synthase, inducible; IRF3, Interferon regulatory factor 3; IRF7, 
Interferon regulatory factor 7; IFNs, interferons. 
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Supplementary Figure 2.2. Knockdown of Phf15 increases the magnitude of the 
microglial inflammatory response after TLR9 stimulation. Time course experiments 
showing relative mRNA expression levels of Tnfα (A) and Nos2 (C) after CpG ODN 
stimulation of Phf15 knockdown microglial SIM-A9 cells compared to shCtrl (control 
scrambled shRNA). Tnfα and Nos2 expression at time point 0 from the time course 
experiments are displayed separately in (B) and (D), respectively. Data are mean ± SEM (n 
= 3 per condition). Unpaired t-tests for shPhf15-1 or shPhf15-2 and shCtrl cells for 
individual timepoints: asterisks indicate *p<0.05, **p<0.01, ***p<0.001,****p<0.0001. 
Knockdown efficiency for cell lines shPhf15-1 and shPhf15-2 compared to shCtrl is shown 
in Figure 2.2a. CpG ODN, CpG Oligodeoxynucleotide; Tnfα, Tumor necrosis factor alpha; Nos2, Nitric 
oxide synthase, inducible. 
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Supplementary Figure 2.3. Knockdown of Phf15 increases the magnitude of the 
microglial inflammatory response after TLR3 activation. 24-hour time course 
experiments showing relative mRNA expression levels of Tnfα (A) and Nos2 (C) after 
Poly(I:C) stimulation of Phf15 knockdown microglial SIM-A9 cells compared to shCtrl 
(control scrambled shRNA). Tnfα and Nos2 expression at time point 0 from the time course 
experiments are displayed separately in (B) and (D), respectively. Data are mean ± SEM (n 
= 3 per condition). Unpaired t-tests for shPhf15-1 or shPhf15-2 and shCtrl cells for 
individual timepoints: asterisks indicate *p<0.05, **p<0.01, ***p<0.001,****p<0.0001. 
Knockdown efficiency for cell lines shPhf15-1 and shPhf15-2 compared to shCtrl is shown 
in Figure 2.2a. 
Poly(I:C), Polyinosinic:polycytidylic acid; Tnfα, Tumor necrosis factor alpha; Nos2, Nitric 
oxide synthase, inducible. 
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Supplementary Figure 2.4. Knockout of Phf15 followed by TLR9 stimulation 
increases the magnitude and duration of inflammatory gene expression. 24-hour time 
course experiments showing relative mRNA expression levels of proinflammatory factors, 
Tnfα (A), Il-1β (C), and Nos2 (E) after CpG ODN stimulation. Tnfα, Il-1β and Nos2 
expression at time point 0 from the time course experiments are displayed separately in 
(B), (D) and (F), respectively. All data are mean ± SEM (n = 3 per condition). Unpaired t-
tests between Phf15 KO and control cells for percent reduction and for individual 
timepoints: asterisks indicate *p<0.05, **p<0.01, ***p<0.001,****p<0.0001. 
Percent reduction in Phf15 transcript expression in Phf15 knockout SIM-A9 microglia 
compared to control is shown in Figure 2.3a. 
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CpG ODN, CpG Oligodeoxynucleotide; Tnfα, Tumor necrosis factor alpha; Il-1β, Interleukin 
1 beta; Nos2, Nitric oxide synthase, inducible. 
 
 
Supplementary Figure 2.5. Knockout of Phf15 followed by TLR3 activation increases 
expression of Il-1β. (A) 24-hour time course experiment showing relative mRNA 
expression levels of Il-1β after Poly(I:C) stimulation. Il-1β expression at time point 0 from 
the time course experiments is displayed separately in (B). All data are mean ± SEM (n = 3 
per condition). Unpaired t-tests between Phf15 knockout and control cells for individual 
timepoints: asterisks indicate *p<0.05, **p<0.01, ****p<0.0001. 
Percent reduction in Phf15 transcript expression in Phf15 knockout SIM-A9 microglia 
compared to control is shown in Figure 2.3a. 
CpG ODN, CpG Oligodeoxynucleotide; Il-1β, Interleukin 1 beta. 
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Supplementary Figure 2.6. Phf15 overexpression dampens the microglial 
inflammatory response after TLR9 stimulation. 
24-hour time course experiments showing relative mRNA expression levels of Tnfα (A), Il-
1β (C), and Nos2 (E) after CpG ODN stimulation. Tnfα, Il-1β and Nos2 expression at time 
point 0 from the time course experiments are displayed separately in (B), (D) and (F), 
respectively. All data are mean ± SEM (n = 3 per condition). Unpaired t-tests between 
Phf15 OE and control cells for fold-overexpression and for individual timepoints: asterisks 
indicate *p<0.05, ****p<0.0001.  
Fold overexpression (OE) of Phf15 in SIM-A9 microglia compared to control cells is shown 
in Figure 2.4a. 
  33 
CpG ODN, CpG Oligodeoxynucleotide; Tnfα, Tumor necrosis factor alpha; Il-1β, Interleukin 
1 beta; Nos2, Nitric oxide synthase, inducible. 
 
 
Supplementary Figure 2.7. Phf15 overexpression dampens the microglial 
inflammatory response after TLR3 activation. 
24-hour time course experiments showing relative mRNA expression levels Tnfα (A), Il-1β 
(C), and Nos2 (E) after Poly(I:C) stimulation. Tnfα, Il-1β and Nos2 expression at time point 
0 from the time course experiments are displayed separately in (B), (D) and (F), 
respectively. All data are mean ± SEM (n = 3 per condition). Unpaired t-tests between 
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Phf15 OE and control cells for fold-overexpression and for individual timepoints: asterisks 
indicate *p<0.05, **p<0.01.  
Fold overexpression of Phf15 in SIM-A9 microglia compared to control cells is shown in 2. 
4a. 
Poly(I:C), Polyinosinic:polycytidylic acid; Tnfα, Tumor necrosis factor alpha; Il-1β, 
Interleukin 1 beta; Nos2, Nitric oxide synthase, inducible. 
 
 
Supplementary Figure 2.8. Loss of Phf15 leads to downregulation of genes 
involved in growth, differentiation and glial cell migration processes under 
baseline conditions. RNA-seq was performed on Phf15 knockout SIM-A9 microglia 
under No stimulation conditions shown in Figure 2.5. (A) GO analysis for biological 
process categories for the set of significantly downregulated genes in Phf15 knockout SIM-
A9 microglia is shown. Biological categories center around various cell growth and 
differentiation processes and glial cell migration. (B) Enriched transcription factor binding 
motifs for the set of downregulated genes in the No stimulation (baseline) condition 
include Twist2 and MIST1/BHLHA15. 
Twist2, Twist-related protein 2; MIST1/BHLHA15, basic helix–loop–helix 15. 
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Supplementary Figure 2.9. Knockout of Phf15 leads to downregulation of genes 
involved in regulation of defense response and cytokine production 6 hours after 
LPS stimulation. RNA-seq was performed on Phf15 knockout SIM-A9 microglia after 
LPS stimulation shown in Figure 2.6. (A) GO analysis for biological process categories for 
the set of significantly downregulated genes in Phf15 knockout SIM-A9 microglia is shown. 
(B) Enriched transcription factor binding motifs for the set of downregulated genes after 
LPS stimulation include ISRE (IRF binding motif), IRF1 and IRF3 binding motifs. 
ISRE, Interferon (IFN) stimulated response element; IRF1, IFN response factor 1; IRF3, 
IFN response factor 3. 
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Supplementary Figure 2.10. Knockout of Lsd1 increases expression of 
proinflammatory factors in microglia. Relative mRNA expression levels of Tnfα  (A) and 
Il-1b (B) were increased in microglia of Lsd1 KO mice compared to WT after immune 
stimulation. Data are mean ± SEM (n = 3 mice per condition). Two-way ANOVA with post 
hoc Sidak’s comparisons within timepoint between groups: asterisks denote ****p<0.0001. 
Tnfα, tumor necrosis factor alpha; Il-1β, Interleukin 1 beta; Lsd1, Lysine specific 
demethylase 1. 
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Supplementary Figure 2.11. PHF15 does not inhibit proinflammatory gene 
expression via degradation of LSD1 in mouse microglia. 
(A) LSD1 is associated with the CoRest co-repressor complex which inhibits inflammatory 
gene expression. (B) Ubiquitylation of LSD1 by PHF15 targets it for degradation, releasing 
inhibition of inflammatory gene expression. (C) In our model, PHF15 interacts with an 
unknown transcription factor(s) that putatively bind(s) to ISRE or IRF, AP-1 or other 
transcription factor binding motifs to inhibit inflammatory gene expression. 
Lsd1, Lysine specific demethylase 1; CoREST, REST corepressor 1 (also RCOR1); 
HDAC1/2, Histone deacetylase complex 1/2; TF, transcription factor; ISRE, Interferon-
stimulated response element; IRF, Interferon regulatory factor; AP-1, Activator protein 1. 
 
Supplementary Table 2.1. List of qPCR primers 
? inflammatory gene expression
TF
CoREST
Ub
Ub
Ub
Ub
LSD1
HDAC1/2
PHF15
inflammatory gene 
expression
PHF15
TF
CoREST
LSD1HDAC1/2
inflammatory gene 
expression
A B
C
Gene Direction Sequence 
Phf15 + TCAGCATCAAGATGTTCCAAACT 
 - TGAGCTGGTATGAATCTGGGA 
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Phf15, PHD finger protein 15; Tnfα, Tumor necrosis factor alpha; Nos2, Nitric oxide           
synthase, inducible; Il-1β, Interleukin 1 beta; Hprt, Hypoxanthine 
Phosphoribosyltransferase. 
  
Tnfα + CCCTCACACTCAGATCATCTTCT 
 - GCTACGACGTGGGCTACAG 
Nos2 + GTTCTCAGCCCAACAATACAAGA 
 - GTGGACGGGTCGATGTCAC 
Il-1β + CGTGGACCTTCCAGGATGAG 
 - CGTCACACACCAGCAGGTTA 
Hprt + TCAGTCAACGGGGGACATAAA 
 - GGGGCTGTACTGCTTAACCAG 
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Chapter 3: Loss of STING function inhibits age-related increase in Il-6 expression 
but does not improve motor and memory function in aged mice 
 
Section 3.1: Rationale 
 
Given its role in mediating production of the senescence-associated secretory 
phenotype (SASP) 56 and the role of cellular senescence in inflammaging and 
associated age-related dysfunction 2, I wanted to test in collaboration with the Raulet 
laboratory whether mice lacking a functional Cyclic GMP-AMP (cGAMP) synthase 
(cGAS)-Stimulator of interferon genes (STING) (cGAS-STING) pathway would be 
protected from increased aging-related inflammation and associated deficits in brain 
function. I used p16-3MR GT mice, a cross between the senescent cell-labeling p16-
3MR mouse strain 166 and Goldenticket (GT) mice which lack functional STING and are 
impaired in Type I interferon (IFN-I) production 167. Additionally, I wished to determine 
whether, at the molecular level, STING might lead to inhibition of Phf15 in order to 
increase brain inflammation. I recently described Phf15 as a negative regulator of 
microglia inflammatory function that regulates both classical and antiviral inflammatory 
responses 168. Inhibition of Phf15 via cGAS-STING would result in increased expression 
of IFN-I-dependent antiviral mediators and proinflammatory chemokines leading to 
increased inflammation. 
 
 
Section 3.2: Results 
 
Loss of STING does not improve motor coordination in old or middle-aged mice 
 
To determine whether loss of STING might protect mice from aging-related deficits in 
motor coordination that are typically seen in both humans 169 and mice 170, I tested male 
and female p16-3MR GT mice and sex and age-matched controls (CON p16-3MR) on 
the rotarod at 10 and 26 months of age. The rotarod is an apparatus which consists of a 
horizontal, rotating bar. Mice are placed on the bar and the latency to fall, that is how 
long they are able to remain on the bar, is measured as a proxy for motor coordination 
and balance with longer latencies correlating to better performance 171,172. Male and 
female mice were tested separately due to reported sex differences in rotarod 
performance 173. 
There was no significant difference for the time mice remained on the bar 
between p16-3MR GT and control mice at 26 months of age for either gender (Figure 
3.1A, B) for any of the testing days. Mice also did not improve, i.e., increase the length 
of time they remained on the bar between any two testing days (Figure 3.1C, D). 
Previous studies have indicated that rotarod performance is negatively correlated with 
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body weight 170,173, but I found no differences in body weight between 26-month old p16-
3MR GT and control mice for either gender (Figure 3.1E, F), thus body weight was not a 
confound for this experimental group. 
 
 
Figure 3.1. Loss of STING does not improve motor coordination in old (26 month-
old) mice (A) Ther  was no significant difference in time on bar between 26 month-old STING-
deficient (p16-3MR GT, blue bars) and control (CON (p16-3MR), open bars) male mice on 
the rotarod for any of the testing days. Data are mean ± SEM (n = 7 CON (p16-3MR), n = 3 
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p16-3MR GT).  
(B) There was no significant difference in time on bar between 26 month-old STING-
deficient (p16-3MR GT, red bars) and control (CON (p16-3MR), open bars) female mice on 
the rotarod over 3 days of testing. Data are mean ± SEM (n = 4 CON (p16-3MR), n = 4 
p16-3MR GT). 
(C) There was no significant difference in latency to fall between testing days (i.e., 
difference in the day-to-day time that mice spent on the bar) for male mice between STING 
knockout (p16-3MR GT, blue bars) and control mice (CON (p16-3MR), open bars). Data 
are mean ± SEM (n = 7 CON (p16-3MR), n = 3 p16-3MR GT). 
(D) Same as (C) but for female mice (p16-3MR GT, red bars; CON (p16-3MR), open bars). 
Data are mean ± SEM (n = 4 CON (p16-3MR), n = 4 p16-3MR GT). (A-D) RM 2-way 
ANOVA with Sidak’s multiple comparisons between genotype by day. 
(E) There was no significant difference in body weight between STING knockout male (p16-
3MR GT, blue dots) and control mice (CON (p16-3MR), black dots). Data are mean ± SEM 
(n = 7 CON (p16-3MR), n = 3 p16-3MR GT). Unpaired t-test. 
(F) Same as (C) but for female mice. Data are mean ± SEM (n = 4 CON (p16-3MR), n = 4 
p16-3MR GT). Unpaired t-test. 
 
 
There was also no significant difference for time on bar between p16-3MR GT 
and control mice at 10 months of age for males and females (Figure 3.2A, C and 3.2B, 
D, respectively), although control males showed significant improvement between days 
1 and 2, as well as, days 1 and 3 of testing (Figure 3.2A). There was a significant 
increase in body weight between 10-month old male p16-3MR GT and controls (Figure 
3.2E), which did not translate into decreased time on bar for the heavier, p16-3MR GT 
group. However, this may possibly account for why control mice improved between days 
1 and 2 and days 1 and 3 and p16-3MR GT mice did not. There was no significant 
difference in body weight between 10-month old p16-3MR GT and control female mice 
(Figure 3.2F). Overall, I found no differences in rotarod performance between p16-3MR 
GT mice and age-matched controls for either gender in old and middle age, indicating 
that loss of STING is not protective for age-related deficits in motor coordination. 
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Figure 3.2. Loss of STING does not improve motor coordination in middle-aged (10 
month-old) mice 
(A) There was a significant main effect of day (F 1.813, 16.32 = 10.91, p = 0.0012) for 10 
month-old CON (p16-3MR) male mice (open bars) for time on bar between day 1 and day 
2, as well as, day 1 and day 3 compared to p16-3MR GT (STING-deficient) mice (blue 
bars). There was no interaction between testing day and genotype. Data are mean ± SEM 
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(n = 8 CON (p16-3MR), n = 3 p16-3MR GT).  
(B) There was no significant difference in time on bar between 10 month-old STING-
deficient female mice (p16-3MR GT, red bars) versus control (CON (p16-3MR), open bars) 
on the rotarod over the 3 testing days. Data are mean ± SEM (n = 4 CON (p16-3MR), n = 3 
p16-3MR GT).  
(C) There was no significant difference in latency to fall between testing days (i.e., 
difference in the day-to-day time that mice spent on the bar) for male mice between STING 
knockout (p16-3MR GT, blue bars) and control mice (CON (p16-3MR), open bars). Data 
are mean ± SEM (n = 8 CON (p16-3MR), n = 3 p16-3MR GT). 
(D) Same as (A) but for female mice (p16-3MR GT, red bars; CON (p16-3MR), open bars). 
Data are mean ± SEM (n = 4 CON (p16-3MR), n = 3 p16-3MR GT). (A-D) RM 2-way 
ANOVA with Sidak’s multiple comparisons between genotype by day. 
(E) There was a significant increase in body weight in STING knockout male (p16-3MR GT, 
blue dots) compared to control mice (CON (p16-3MR), black dots). Data are mean ± SEM 
(n = 8 CON (p16-3MR), n = 3 p16-3MR GT). Unpaired t-test: *p<0.05. 
(F) There was no significant difference in body weight between STING knockout female 
(p16-3MR GT, red dots) and control mice (CON (p16-3MR), black dots). Data are mean ± 
SEM (n = 4 CON (p16-3MR), n = 3 p16-3MR GT). Unpaired t-test. 
 
 
Loss of STING does not decrease proinflammatory cytokine or chemokine 
expression in cerebellum in old mice 
 
Inflammatory changes in the brain can precede the onset of behavioral deficits, thus I 
tested whether STING deficiency might prevent proinflammatory cytokine and 
chemokine expression in cerebellum, which mediates motor coordination and aspects of 
locomotor behavior. I found no significant difference in mRNA expression levels of 
Interleukin-6 (Il-6) or C-C motif chemokine ligand 20 (Ccl20) in the cerebellum of old, 27 
month-old mice (Figure 3.3A, B, respectively), although there was a significant decrease 
in young (4.5 month-old) STING knockout mice compared to age-matched controls 
(Figure 3.3A). Overall, loss of STING does not significantly decrease expression of 
proinflammatory factors in the cerebellum in old mice. 
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Figure 3.3. STING deficiency does not decrease expression of proinflammatory 
mediators in the cerebellum of aged mice 
(A) There was a significant difference in mRNA expression of Il-6 in cerebellum between 
p16-3MR GT (purple bars) and control mice (CON (p16-3MR), open bars) in young, 4.5 
month-old mice but no difference in old, 27 month-old mice. 
(B) There were no significant differences in Ccl20 mRNA levels in cerebellum between p16-
3MR GT (purple bars) and control mice (CON (p16-3MR), open bars) in young, 4.5 month-
old mice nor old, 27 month-old mice.  
All data are mean ± SEM (n = 4-6 young 4.5 month-old mice per genotype, n = 5-7 old 27 
month-old mice per genotype). Unpaired t-test between genotype for each age group: 
*p<0.05. 
Il-6, interleukin 6; Ccl20, C-C motif chemokine ligand 20. 
 
 
Loss of STING does not improve working memory in old or middle-aged mice 
 
In order to assess whether loss of STING might improve cognitive function in old and 
middle aged mice, I tested p16-3MR GT and control mice on the Y maze–a test for 
working memory at 10 and 26 months of age (Figure 3.4A). Working memory is one of 
the first cognitive functions to show age-related impairment in humans with an onset of 
about 60 years of age or roughly late middle age. Similarly, working memory deficits 
have been noted in mice at 10 and 24-26 months of age 174. The Y maze is used to 
assess working memory by measuring spontaneous alternation 175. The apparatus 
consists of three identical plastic arms set at 120° from each other. The number of 3 
consecutive entries in different arms is considered an alternation triplet (e.g. ABC or 
BCA or CAB) with the percent alternation triplet calculated as: (Number of alternation 
triplets x 100)/(Max Alternation Triplet) where the Max Alternation Triplet = Total Arm 
Entries –2. Greater percent alternation triplet indicates better working memory performance.  
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Figure 3.4. Loss of STING does not improve working memory in old nor middle-aged 
mice  (A) Timeline for Y maze testing. 
(B) There was no significant difference in % Alternation triplet between male (blue bars) 
and female mice (red bars) within genotype at 26 months of age. Data are mean ± SEM (n 
= 5 male, n = 4 female CON (p16-3MR); n = 3 male, n = 4 female p16-3MR GT).  
(C) There was no significant difference in % Alternation triplet between male (blue bars) 
and female mice (red bars) within genotype at 10 months of age. Data are mean ± SEM (n 
= 7 male, n = 4 female CON (p16-3MR); n = 3 male, n = 3 female p16-3MR GT).  
(B and C) Unpaired t-test within genotype between males and females for each age group. 
(D) There was no significant difference in % Alternation triplet between 26 month-old 
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STING-deficient (p16-3MR GT, purple bars) and control mice (CON(p16-3MR), open bars). 
Data are mean ± SEM (n = 10 CON (p16-3MR), n = 7 p16-3MR GT) 
(E) There was no significant difference in % Alternation triplet between 10 month-old 
STING-deficient (p16-3MR GT, purple bars) and control mice (CON(p16-3MR), open bars). 
Data are mean ± SEM (n = 12 CON (p16-3MR), n = 6 p16-3MR GT). 
(D and E) Unpaired t-test between genotype for each age group. 
 
 
There were no differences in % alternation triplet between male and female mice 
within genotype (Figure 3.4B, C) so males and females were pooled for statistical 
analysis. I found no significant difference in % alternation triplet indicating no differences 
in working memory performance between p16-3MR GT and control animals at 26 and 
10 months of age (Figure 3.4D, E, respectively). Overall, my results indicate that loss of 
STING does not improve working memory performance in old (26 months) and middle 
(10 months) of age.  
 
Loss of STING significantly decreases levels of proinflammatory cytokine Il-6 in 
the hippocampus of old mice 
 
To test whether loss of STING might suppress proinflammatory cytokine and chemokine 
expression in brain areas mediating working memory function, I tested mRNA 
expression levels of Il-6, Ccl5, Ccl20 and C-X-C motif chemokine 10 (Cxcl10) in the 
hippocampus of old (27 month-old) and young (4.5 month-old) p16-3MR GT and age-
matched control (CON (p16-3MR)) mice. 
 I found significantly reduced mRNA expression of Il-6, a proinflammatory cytokine 
and a key mediator of the SASP in the hippocampus of old (27-month old) p16-3MR GT 
mice compared to controls (Figure 3.5A). Importantly, there was a significant effect of 
age and genotype, as well as, an age x genotype interaction, indicating that the age-
related Il-6 increase is less pronounced in STING knockout mice. Il-6 has been shown 
to promote the production of new astrocytes 176 and oligodendrocytes 177 (both types of 
glial cells in the brain) diverting neural stem cells into making new glia at the expense of 
generating new neurons. Thus, I hypothesized that decreased Il-6 expression in p16-
3MR GT mice might prevent production of new glia while preserving neurogenesis–the 
generation of new neurons. I measured mRNA expression of Glutamate aspartate 
transporter 1 (Glast), an astrocytic marker, in the hippocampus of young and old p16-
3MR GT and control mice. Although there was a significant difference in Glast levels in 
young (4.5 month-old) mice this difference was not present in the old (27 month-old) 
mice (Figure 3.5B). There were also no significant differences in mRNA expression 
levels of other proinflammatory factors, the chemokines Ccl5 (Figure 3.5C), Ccl20 
(Figure 3.5D) and Cxcl10 (Figure 3.5E). Overall, loss of STING led to significantly 
decreased levels of Il-6 in the hippocampus of old mice but I found no difference in 
expression of other inflammatory factors. 
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Figure 3.5. Loss of STING decreases proinflammatory cytokine Il-6 expression in 
hippocampus of old mice 
(A) mRNA expression levels of Il-6 were significantly reduced in hippocampus of old, 27 
month-old STING knockout mice (p16-3MR GT, purple bars) compared to control (CON 
(p16-3MR), open bars). There was a significant main effect of age (F 1,8 = 49.79, p = 0.001) 
and genotype (F 1, 10 = 17.31, p = 0.0019), as well as, a significant age x genotype 
interaction (F 1,8 = 7.772, p = 0.0236). 2-way ANOVA followed by Sidak’s post hoc 
comparisons: *** p<0.001. 
(B) There was a significant decrease in mRNA expression levels of Glast in hippocampus 
of 4.5 month-old STING knockout mice (p16-3MR GT, purple bars) compared to control 
(CON (p16-3MR), open bars). There was no significant difference at 27 months of age. 
Unpaired t-test between control and p16-3MR GT within age group: *p<0.05.  
(C) There was no significant difference in Ccl5 mRNA expression in hippocampus of 4.5 or 
27 month-old STING knockout mice (p16-3MR GT, purple bars) compared to control (CON 
(p16-3MR), open bars). Unpaired t-test between control and p16-3MR GT within age group.  
(D) There was no significant difference between p16-3MR GT (purple bars) and control 
mice (CON (p16-3MR), open bars) in Ccl20 mRNA expression in hippocampus at 4.5 or 27 
months of age. Unpaired t-test between control and p16-3MR GT within age group 
(E) There was no significant difference in Cxcl10 mRNA expression in hippocampus of 4.5 
or 27 month-old STING knockout mice (p16-3MR GT, purple bars) compared to control 
(CON (p16-3MR), open bars). Unpaired t-test between control and p16-3MR GT within age 
4.5
 m
on
th-
old
27 
mo
nth
-ol
d
0
1
2
3
Il-
6
Re
lat
ive
 m
RN
A 
ex
pr
es
sio
n
***
4.5
 m
on
th-
old
27 
mo
nth
-ol
d
0
2
4
6
Cc
l5
Re
lat
ive
 m
RN
A 
ex
pr
es
sio
n
4.5
 m
on
th-
old
27 
mo
nth
-ol
d
0.0
0.5
1.0
1.5
2.0
Gl
as
t
Re
lat
ive
 m
RN
A 
ex
pr
es
sio
n
*
CON (p16-3MR)
p16-3MR-GT
4.5
 m
on
th-
old
27 
mo
nth
-ol
d
0
1
2
3
4
Cc
l20
Re
lat
ive
 m
RN
A 
ex
pr
es
sio
n
4.5
 m
on
th-
old
27 
mo
nth
-ol
d
0
10
20
30
40
Cx
cl1
0
Re
lat
ive
 m
RN
A 
ex
pr
es
sio
n
A B
C D E
  48 
group.  
All data are mean ± SEM (n = 4-6 young, 4.5 month-old mice per genotype; n = 5-7 old, 27 
month-old mice per genotype). 
Il-6, interleukin 6; Glast, Glutamate aspartate transporter 1; Ccl5, C-C motif chemokine 
ligand 5; Ccl20, C-C motif chemokine ligand 20; Cxcl10, C-X-C motif chemokine 10. 
 
 
Loss of STING does not affect expression of Phf15 in the brain 
 
Because the cGAS-STING pathway is an important positive regulator of IFN-I gene 
expression 178 and it has been observed that IFN-Is facilitate senescence 179, I 
wondered whether STING might regulate age-induced proinflammatory gene expression 
via inhibition of Phf15, a negative regulator of microglia inflammatory function and 
specifically, the microglial antiviral response 168. I hypothesized that Phf15 expression 
might be significantly increased in p16-3MR GT mice compared to age-matched 
controls. I tested mRNA levels of Phf15 in hippocampus, cerebellum and frontal cortical 
areas (which mediate memory, motor coordination and executive function, respectively) 
in 4.5 and 27 month-old p16-3MR GT mice compared to controls. I found no significant 
differences in Phf15 expression in any of the brain regions examined or for any age 
group (Figure 3.6A-C). 
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Figure 3.6. Loss of STING does not affect Phf15 mRNA expression levels in the brain 
There was no significant difference in Phf15 mRNA expression in: 
(A) hippocampus,  
(B) frontal cortical regions or 
(C) cerebellum of 4.5 or 27 month-old STING knockout mice (p16-3MR GT, purple bars) 
compared to control (CON (p16-3MR), open bars).  
All data are mean ± SEM (n = 4-6 young, 4.5 month-old mice per genotype; n = 5-7 old, 27 
month-old mice per genotype). Unpaired t-test between control and p16-3MR GT within 
age group. 
 
 
For frontal cortical regions, there was also no significant difference in mRNA 
expression levels of proinflammatory factors Il-6 or Ccl20 (Figure 3.7A, B). Overall, my 
data suggest that STING-mediated production of the SASP in the aged brain likely does 
not occur via decreased levels of Phf15. 
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Figure 3.7. Loss of STING does not decrease proinflammatory cytokine/chemokine 
expression in frontal cortical regions 
(A) and (B) There were no significant differences in Il-6 (A) or Ccl20 (B) mRNA expression 
between p16-3MR GT (purple bars) and control mice (CON (p16-3MR), open bars) in 
frontal cortical areas at 4.5 or 27 months of age. 
All data are mean ± SEM (n = 4-6 young 4.5 month-old mice per genotype, n = 5-7 old 27 
month-old mice per genotype). Unpaired t-tests between genotype for each age group. 
Il-6, interleukin 6; Ccl20, C-C motif chemokine ligand 20. 
 
 
Section 3.3: Discussion 
 
Overall, I found that STING deficiency leads to decreased expression of 
proinflammatory cytokine Il-6 in the hippocampus of old, 27 month-old mice compared 
to controls. The hippocampus which mediates various memory-related processes 
including working memory, is particularly sensitive to aging-related dysfunction 180. 
Previous studies have found that Il-6 can skew neural stem cell differentiation towards 
the generation of new astrocytes (astrogliogenesis) 176 at the expense of generating 
new neurons. However, I did not find decreased mRNA expression of Glast, a marker of 
astrocytes and proxy for astrocyte numbers, in the hippocampus of 27 month-old 
STING-deficient mice compared to controls. Additionally, I did not find decreased 
expression of other cytokines or chemokines characteristic of the SASP in hippocampus 
nor related functional improvements in working memory in STING-deficient mice 
compared to age-matched controls. Taken together, my results suggest that although 
loss of STING decreased Il-6 in hippocampus, this decrease did not translate into 
improved working memory function. It is possible that the spontaneous alternation 
protocol used with the Y maze is not sensitive enough to detect more subtle deficits in 
working memory function and a larger battery of working memory assays might have 
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been beneficial in order to discriminate between normal and impaired function. Similarly, 
I found no difference in performance on a motor coordination task or significant 
differences in inflammatory cytokine/chemokine expression in the cerebellum (the area 
of the brain responsible for regulating voluntary movement, including motor coordination 
and balance) between aged STING knockout and control animals.  
The cGAS-STING pathway is an important regulator of SASP gene expression at 
the molecular level, mediating the production of inflammatory chemokines (CXCL10 and 
various CCL’s including CCL5 and SP CCL20) and IFN-I responses via activation of the 
transcription factors Interferon regulatory factor 3 IRF3 181,182 and Signal transducer and 
activator of transcription 6 (STAT6) 183. I have previously shown that Phf15 is a 
repressor of microglial inflammatory function, which regulates the antiviral response as 
well as proinflammatory cytokine expression 168. Due to the similarity of the 
inflammatory response resulting from the cGAS-STING pathway and that mediated by 
Phf15, i.e., the activation of IRF3 to mediate IFN-I responses, I hypothesized that during 
aging, cells undergoing senescence might lead to expression of the SASP via 
downregulation of Phf15. Thus, I might observe decreased Phf15 mRNA levels in the 
brains of control mice but not STING-deficient mice. Although I used a bulk tissue 
approach to measure Phf15 expression levels, in the brain Phf15 is almost exclusively 
expressed in microglia (Figure 3.8) 184. Thus, bulk tissue Phf15 mRNA expression 
mostly reflects microglial Phf15. I did not find significant differences in Phf15 mRNA 
levels between STING knockout and age-matched controls in any of the brain regions 
tested (hippocampus, cerebellum, frontal cortical regions) indicating that positive 
regulation of antiviral IFN-I-related gene expression via cGAS-STING might not act 
through inhibition of Phf15. Putatively, Phf15 may work to repress pathogen-associated 
molecular patterns (PAMPs)/Toll-like receptor (TLR)-mediated inflammatory responses, 
as opposed to, cytosolic DNA-sensing by cGAS-STING. For example, the TLR4 and 
TLR3 signaling pathways which can activate classic proinflammatory and IFN-I 
responses via Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) 
and IRF3. 
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Figure 3.8. Phf15 is almost exclusively expressed in microglia in the brain. Histogram 
obtained from Brain RNA-seq, RNA-seq of cell types isolated from mouse brain 
(http://www.brainrnaseq.org/) 
 
 In summary, although the cGAS-STING pathway is involved in regulation of the 
SASP during aging-related cellular senescence, I found only slight decreases in 
proinflammatory cytokine expression in hippocampus and no improvement in memory or 
motor function during old age in STING knockout mice. Additionally, my results suggest 
that expression of SASP-related inflammatory factors by the cGAS-STING pathway 
might not proceed via inhibition of Phf15. 
 
 
Section 3.4: Materials and Methods 
 
3.4.1: Ethics Statement 
 
This study was carried out in accordance with the recommendations in the Guide for the 
Care and Use of Laboratory Animals of the National Institutes of Health. The Animal 
Use Protocol (AUP-2017-02-9539) was approved by the Animal Care and Use 
Committee of the University of California, Berkeley. 
 
3.4.2: Animals  
 
p16-3MR BL/6 mice were obtained from the laboratory of Judith Campisi (Buck Institute 
for Research on Aging, Novato, CA). C57BL/6J-Sting1gt/J mice (Goldenticket, GT) were 
purchased from the Jackson Laboratory. GT mice were genotyped via amplification and 
sequencing of exon 6 of Sting which contains the T596A mutation using the following 
primers: Exon 6-For, 5′-TCACACTGAGAAGGCTAACGAGC-3′; Exon 6-Rev, 5′-
CACCATAGAACAGGGATCACGC-3’. p16-3MR BL/6 mice were crossed to 
homozygous GT mice and the p16-3MR genotype was confirmed via PCR using the 
following primers:  For GACGTGCCTCCACAGGTAG; Rev CGAGAACGCCGTGATTTT. 
Mice were maintained on a 12:12-h light–dark cycle (lights on at 0700 hours) with ad 
libitum access to food and water. All animal care and procedures were approved by the 
University of California, Berkeley Animal Care and Use Committee. 
 
3.4.3: Behavioral Studies 
 
Rotarod. The rotarod tests motor coordination and balance 171,172. Mice were placed on 
on a horizontal, accelerating rotating cylinder (Rota-rod 47650, Ugo Basile, Italy) and 
the latency to fall–a measure of the mouse’s balance, coordination and general physical 
condition–was noted. Mice were tested over 3 consecutive days. Each daily session 
included a training run of 300 seconds at 5 rpm followed by 1 hour of rest and 3 
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consecutive accelerating (5-40 rpm for 300 seconds) trials with an inter-trial interval of 
~30 minutes. All trials were video recorded and latency to fall was scored by 2 blind 
observers. Male and female animals were tested separately. 
 
Y maze. The Y maze was used to assess working memory by measuring spontaneous 
alternation 175. The apparatus consisted of three identical plastic arms set at 120° from 
each other. Individual subject mice were placed in the center portion of the maze and 
were allowed to freely explore for 10 minutes. Movement in the Y maze was tracked, 
recorded and analyzed using the SMART 3.0 Video Tracking Software (Panlab; Harvard 
Apparatus, Holliston, MA). Three consecutive entries into three different arms was 
considered an alternation triplet (e.g. ABC or BCA or CAB). Percent alternation triplet 
was calculated as: (Number of alternation triplets x 100)/(Max Alternation Triplet) where 
the Max Alternation Triplet = Total Arm Entries –2. Males and females were tested 
separately but results for all animals were pooled by age group for statistical analysis. 
 
3.4.4: RNA extraction 
Mice were quickly sacrificed according to the approved protocol. Brains were isolated 
and frontal cortical areas, hippocampus and cerebellum were dissected, flash frozen 
and stored at − 80 °C. RNA was extracted using a bead homogenizer (30 seconds, 
setting ‘5’’; Bead Mill, VWR) in Trizol reagent (ThermoFisher, Waltham, MA). After 
homogenization, tubes were incubated at room temperature for 5 min and spun down at 
12,000 g for 5 min at 4C. The supernatant was transferred to a fresh RNase/DNase free 
eppendorf and total RNA was extracted using the Direct-zol RNA miniprep kit (Zymo 
Research, Irvine, CA) according to the manufacturer’s instructions. 
3.4.5: Real-time quantitative PCR (RT-qPCR) 
 
cDNA was reversed transcribed from total RNA using the SuperScript™ III First-Strand 
Synthesis System kit (ThermoFisher, Waltham, MA) following the manufacturer’s 
instructions. RT-qPCR was run using SYBR green (Roche, Pleasanton, CA) on a 
QuantiStudio 6 (ThermoFisher, Waltham, MA) real-time PCR machine. All RT-qCPR 
primers were specific to the desired template, spanned exon-exon junctions and 
captured all transcript variants for the specific gene under study. Primers were designed 
using SnapGene and NCBI Primer BLAST software. Specificity of primer pairs was 
confirmed using melt curve analysis. Ct values were normalized to the housekeeping 
gene Hprt and fold-change differences were determined using the delta-delta Ct (2–∆∆Ct) 
method. Primer sequences used in this study are listed in Table 3.1.  
 
Table 3.1. List of RT-qPCR primers 
 
Gene Direction Sequence 
Phf15 + TCAGCATCAAGATGTTCCAAACT 
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 - TGAGCTGGTATGAATCTGGGA 
Il-6 + GCTACCAAACTGGATATAATCAGGA 
 - CCAGGTAGCTATGGTACTCCAGAA 
Ccl20 + ACTGTTGCCTCTCGTACATACA 
 - GAGGAGGTTCACAGCCCTTTT 
Hprt + TCAGTCAACGGGGGACATAAA 
 - GGGGCTGTACTGCTTAACCAG 
Phf15, PHD finger protein 15; Il-6, Interleukin 6; Ccl20, C-C motif chemokine ligand 20; 
Hprt, Hypoxanthine Phosphoribosyltransferase. 
 
 
3.4.6: Statistical Analysis 
 
Prism 8 software (GraphPad, San Diego, CA) was used for statistical analysis. P values 
were calculated using Unpaired t-tests, repeated measures (RM) 2-way ANOVA or 
ordinary 2-way ANOVA as indicated. 
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Chapter 4: Prolonged high fat feeding and obesity do not affect working memory 
or levels of Phf15 in the mouse brain 
 
Section 4.1: Rationale 
 
Although numerous studies have reported on the effects of high fat diet (HFD) treatment 
on inflammatory markers in the brain, as well as, detrimental effects on cognitive 
function, the length of HFD treatment, behavioral task employed as well as other 
physiological measures (i.e., the loss of synaptic markers, impaired long-term 
potentiation (LTP), etc.) correlated to impaired brain function, varied widely between 
studies 185–188 (for review see 189). Thus, I sought to first determine the length of HFD 
treatment necessary to negatively impact working memory which is one of the earliest 
cognitive abilities to show impairment in humans during aging (alongside executive 
function and processing speed) with an onset of about 60 years of age–roughly late 
middle-age 150. 
Additionally, because HFD increases brain inflammation, I wondered if it might do 
so via decreases in Phf15 which I have previously shown is a repressor of microglial 
inflammatory function 168. Microglia are the major mediators of inflammatory processes 
in the brain and increased numbers of microglia, as well as, increased microglial 
activation have been found after HFD treatment 40,190. I had previously shown that Phf15 
mRNA levels increased in frontal cortical brain regions in 20-month old (‘old mice’)–but 
not 14-month old (‘middle aged’) mice–compared to young 2.5-month old mice during 
healthy aging 168. I proposed that this increase might serve as a protective mechanism 
to counteract aging-induced inflammation and protect brain health. Frontal cortical 
regions mediate various aspects of cognitive function and are selectively affected in 
aging-related neurodegenerative conditions like Parkinson’s disease (PD), Alzheimer’s 
disease (AD) and frontotemporal dementia (FTD) 126,127. I thus hypothesized that HFD-
treated mice would have significantly decreased levels of Phf15 in the brain compared 
to age-matched controls fed a normal chow (NC) diet. 
 
Section 4.2: Results 
 
Prolonged HFD treatment significantly increases weight but does not impair 
working memory in adult mice. 
 
To determine the length of HFD treatment necessary to induce impairments in working 
memory, I tested several cohorts of adult mice on differing lengths of HFD treatment in a 
working memory task, the Y maze. I chose 3 and 5 months of HFD as these were 
standard treatment lengths found to correlate with different types of impaired memory 
function 186,187,189. In addition, I tested an earlier time point, 1.5 months, as well as, a 
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much longer-term exposure, 11 months of HFD by 14 months of age, which is roughly 
equal to mouse ‘middle age.’ 
I found that, compared to age-matched controls, HFD treatment significantly 
increased body weight when applied for 1.5, 3, 5 and 11 months (Figure 4.1A, C, E, 
respectively). However, I did not find any differences in percent alternation triplet for any 
length of HFD treatment (Figure 4.1B, D, F). There was also no significant difference in 
the total number of arm entries (Figure 4.2A, C, E) or total distance traveled in the Y 
maze for any of the treatment groups (Figure 4.2B, D, F). 
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Figure 4.1. HFD treatment significantly increased body weight but did not negatively 
impact working memory. 
(A) 1.5 and 3 months of HFD (light orange and dark orange dots, respectively) significantly 
increased body weight in 4.5 month-old mice compared to control mice fed normal chow 
(NC; black dots).  
(B) There was no difference in percent alternation triplet between mice treated with HFD for 
1.5 (light orange bar) nor 3 months (dark orange bar) compared to NC controls (open bar) 
at 4.5 months of age. (A and B) All data are mean ± SEM (n = 5 NC control, n = 5 HFD for 
1.5 months, n = 10 HFD for 3 months). One-way ANOVA with Tukey’s post hoc tests 
between groups: ***p<0.001. 
(C) 7 month-old mice fed a HFD for 5 months (dark orange dots) weighed significantly more 
than age-matched controls fed NC (black dots).  
(D) There was no difference in percent alternation triplet between 7 month-old mice fed a 
HFD for 5 months (dark orange bar) and aged-matched controls on NC (open bar). (C and 
D) All data are mean ± SEM (n = 7 NC control, n = 8 HFD for 5 months). Unpaired t-tests: 
****p<0.0001. 
(E) 14 month-old mice fed a HFD for 11 months (dark orange dots) had significantly 
increased body weight compared to aged-matched controls fed NC (black dots).  
(F) There was no significant difference in percent alternation triplet between 14 month-old 
mice fed a HFD fro 11 months and age-matched, NC-fed controls. (E and F) All data are 
mean ± SEM (n = 7 NC control, n = 7 HFD for 11 months). Unpaired t-tests: ****p<0.0001. 
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Figure 4.2. Additional information for Y maze testing. 
(A) There was no difference in the total number of arm entries nor total distance traveled 
(B) in the Y maze between mice treated with HFD for 1.5 (light orange bar) nor 3 months 
(dark orange bar) compared to normal chow (NC) controls (open bar) at 4.5 months of age. 
Data are mean ± SEM (n = 5 NC control, n = 5 HFD for 1.5 months, n = 10 HFD for 3 
months). One-way ANOVA with Tukey’s post hoc tests.  
(C) There was no difference in the total number of arm entries nor total distance traveled 
(D) in the Y maze between mice treated with HFD for 5 months (dark orange bar) 
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compared to normal chow (NC) controls (open bar) at 7 months of age. Data are mean ± 
SEM (n = 7 NC control, n = 8 HFD for 5 months). Unpaired t-test. 
(E) There was no difference in the total number of arm entries or total distance traveled  
(F) in the Y maze between mice treated with HFD for 11 months (dark orange bar) 
compared to normal chow (NC) controls (open bar) at 14 months of age. Data are mean ± 
SEM (n = 7 NC control, n = 7 HFD for 11 months). Unpaired t-test. 
 
 
Prolonged HFD treatment does not significantly affect Phf15 mRNA expression in 
frontal cortical regions 
 
I found no difference in Phf15 mRNA levels in frontal cortical regions (Figure 4.3A) 
between middle-aged (14-month old) mice fed a HFD for 12 months and NC-fed, age-
matched controls. Although there was a significant difference in body weight (Figure 
4.3B), fasted blood glucose levels also did not differ (Figure 4.3C). 
 
 
 
Figure 4.3. Phf15 mRNA levels in frontal cortical areas did not differ between HFD 
and NC-fed mice during middle or old age. 
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(A) There was no difference in Phf15 mRNA expression in frontal cortical regions of 14-
month old (‘middle-aged’) mice fed a HFD for 12 months (orange dots) and age-matched 
NC-fed control mice (black dots). Data are mean ± SEM (n = 5 NC control, n = 8 HFD). 
Unpaired t-tests. 
(B) There was a significant difference in body weight between 14-month old mice fed a 
HFD for 12 months and age-matched NC-fed control animals. Data are mean ± SEM (n = 5 
NC control, n = 14 HFD). Unpaired t-test: ****p<0.0001. 
(C) There was no difference in blood glucose levels between 14-month old (middle-aged) 
mice fed a HFD for 12 months (orange dots) and age-matched NC-fed control mice (black 
dots). Data are mean ± SEM (n = 5 NC control, n = 15 HFD). Unpaired t-test. 
 (D) There was no difference in Phf15 mRNA expression in frontal cortical regions of 20-
month old (‘old’) mice fed a HFD for 18.5 months (orange dots) and age-matched NC-fed 
control mice (black dots). Data are mean ± SEM (n = 12 NC control, n = 13 HFD). Unpaired 
t-tests. 
(E) There was no significant difference in body weight between 20-month old mice fed a 
HFD for 18.5 months and age-matched NC-fed control animals. Data are mean ± SEM (n = 
13 NC control, n = 13 HFD). Unpaired t-test. 
(F) There was no difference in blood glucose levels between 20-month old (‘old’) mice fed a 
HFD for 18.5 months (orange dots) and age-matched NC-fed control mice (black dots). 
Data are mean ± SEM (n = 12 NC control, n = 8 HFD). Unpaired t-test. 
 
 
There was also no significant difference in Phf15 mRNA expression between old 
(20-month old) mice fed a HFD for 18.5 months and age-matched controls (Figure 4.3D). 
As I had previously shown that Phf15 mRNA levels increased significantly by 20 months 
of age compared to young controls 168, perhaps the HFD intervention lowered this 
increase to control levels. There was no difference in blood glucose levels after a 5-6 
hour fast between mice fed a HFD for 18.5 months compared to age-matched controls 
(Figure 4.3F) or any differences in body weight (Figure 4.3E). 
 
 
Section 4.3: Discussion 
 
Although previous studies have reported memory-related cognitive deficits resulting 
from HFD treatment 186,187,189, I did not find any changes in percent alternation triplet in 
the Y maze, a measure of working memory, for any length of HFD treatment tested in 
this study. As expected, there was a significant increase in body weight for mice at 
different ages and increasing length of HFD, the latter compared to age-matched 
controls, except for the 20-months of age/18.5 months of HFD treatment group.  
I also found no difference in fasted blood glucose at 20 months of age/18.5 
months of HFD nor 14 months of age (‘middle-age’)/12 months of HFD. Although, HFD 
treatment is a widely applied protocol for inducing metabolic dysfunction in mice, studies 
have found divergent responses between increased body weight and fasting blood 
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glucose levels, with some studies finding positive correlations 191 and others finding no 
correlation for similar lengths of HFD treatment 192. In general, the period of HFD 
treatment in these studies (~12 to 20 weeks) tended to be shorter than in the present 
study.  
Prolonged HFD treatment also did not significantly reduce Phf15 mRNA 
expression levels in frontal cortical regions compared to NC-fed, age-matched controls. 
I had previously found increased Phf15 mRNA expression in frontal cortical regions in 
20-month old mice 168 and it is possible that 18.5 months HFD might have reduced this 
aging-related increase to control levels. Overall, although HFD significantly increased 
body weight in mice, I was unable to find any indication of metabolic dysfunction, 
working memory deficits or differences in Phf15 levels in the brain. 
 
 
Section 4.4: Materials and Methods 
 
4.4.1: Ethics Statement 
 
This study was carried out in accordance with the recommendations in the Guide for the 
Care and Use of Laboratory Animals of the National Institutes of Health. The Animal 
Use Protocol (AUP-2017-02-9539) was approved by the Animal Care and Use 
Committee of the University of California, Berkeley. 
 
4.4.2: Animals and Diets 
 
C57BL/6J male mice were purchased from the Jackson Laboratory and randomly 
assigned to NC or HFD (D12492 Rodent Diet with 60 kcal% fat, Research Diets Inc., 
New Brunswick, NJ). HFD supplemented 60% calories from fat, 20% calories from 
carbohydrates and 20% calories from protein. Mice were maintained on a 12:12-h light–
dark cycle (lights on at 0700 hours) with ad libitum access to food and water. All animal 
care and procedures were approved by the University of California, Berkeley Animal 
Care and Use Committee. 
 
4.4.4: Behavioral Studies 
 
Y maze. The Y maze was used to assess working memory by measuring spontaneous 
alternation 175. The apparatus consisted of three identical plastic arms set at 120° from 
each other. Individual subject mice were placed in the center portion of the maze and 
were allowed to freely explore for 10 minutes. Movement in the Y maze was tracked, 
recorded and analyzed using the SMART 3.0 Video Tracking Software (Panlab; Harvard 
Apparatus, Holliston, MA). ). Three consecutive entries into three different arms was 
considered an alternation triplet (e.g. ABC or BCA or CAB). Percent alternation triplet 
was calculated as: (Number of alternation triplets x 100)/(Max Alternation Triplet) where 
the Max Alternation Triplet = Total Arm Entries –2. 
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4.4.5: Blood glucose measurement 
Mice were fasted for 5-6 hours and blood glucose was measured via tail nick using an 
Accu-Chek Performa glucose meter and Accu-Chek Performa test strips (Accu-Chek, 
Roche, Indianapolis, IN). 
 
4.4.6: RNA extraction 
At the indicated ages (14 or 20 months of age), mice were quickly sacrificed according 
to the approved protocol. Brains were isolated and frontal cortical areas were dissected, 
flash frozen and stored at − 80°C. RNA was extracted using a bead homogenizer (30 
seconds, setting ‘5’’; Bead Mill, VWR) in Trizol reagent (ThermoFisher, Waltham, MA). 
After homogenization, tubes were incubated at room temperature for 5 min and spun 
down at 12,000 g for 5 min at 4C. The supernatant was transferred to a fresh 
RNase/DNase free eppendorf and total RNA was extracted using the Direct-zol RNA 
miniprep kit (Zymo Research, Irvine, CA) according to the manufacturer’s instructions. 
4.4.7: Real-time quantitative PCR (RT-qPCR) 
 
cDNA was reversed transcribed from total RNA using the SuperScript™ III First-Strand 
Synthesis System kit (ThermoFisher, Waltham, MA) following the manufacturer’s 
instructions. RT-qPCR was run using SYBR green (Roche, Pleasanton, CA) on a 
QuantiStudio 6 (ThermoFisher, Waltham, MA) real-time PCR machine. All RT-qPCR 
primers were specific to the desired template, spanned exon-exon junctions and 
captured all transcript variants for the specific gene under study. Primers were designed 
using SnapGene and NCBI Primer BLAST software. Specificity of primer pairs was 
confirmed using melt curve analysis. Ct values were normalized to the housekeeping 
gene Hprt and fold-change differences were determined using the delta-delta Ct (2–∆∆Ct) 
method. Primer sequences used in this study are listed in Table 4.1.  
 
Table 4.1. List of RT-qPCR primers 
 
Genes Direction Sequence 
Phf15 + TCAGCATCAAGATGTTCCAAACT 
 - TGAGCTGGTATGAATCTGGGA 
Hprt + TCAGTCAACGGGGGACATAAA 
 - GGGGCTGTACTGCTTAACCAG 
Phf15, PHD finger protein 15; Hprt, Hypoxanthine Phosphoribosyltransferase. 
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4.4.8: Statistical Analysis 
 
Prism 8 software (GraphPad, San Diego, CA) was used for statistical analysis. P values 
were calculated using Unpaired t-tests or 1-way ANOVA as indicated. 
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Chapter 5: Closing Remarks 
 
My work 168 describes the function of a completely novel repressor of microglial 
inflammatory function—PHD finger protein 15 (Phf15)—that may be especially relevant 
in regulating the age-induced microglial proinflammatory phenotype. Using a murine 
microglial cell line (SIM-A9), I showed that Phf15, one of the top 25 microglial genes 
upregulated during healthy aging in humans 100 and a putative epigenetic gene regulator, 
inhibits expression of various proinflammatory mediators (Tumor necrosis factor α 
(Tnfα), Interleukin 1β (Il-1β), Nitric oxide synthase, inducible (Nos2)) under basal (no 
immune stimulation) and signal-dependent activation, i.e., after induction with Toll-like 
receptor (TLR) 4, TLR3 and TLR9 ligands. Importantly, Phf15 also regulates the 
magnitude and duration of the microglial inflammatory response. Because excessive 
and unresolved microglial-mediated inflammation is a key contributor to the 
pathophysiology of many age-dependent neurodegenerative diseases like Parkinson’s 
and Alzheimer’s disease 92–96 finding repressors that can strongly regulate the microglial 
inflammatory response is crucial for possible future therapeutic interventions. 
Importantly, a critical point in the control of inflammation occurs at the level of 
gene transcription with distinct molecular mechanisms regulating different aspects of the 
response. Basal state repression, for example, involves recruitment of co-repressor 
complexes that prevent initiation of inflammatory gene transcription. After immune 
stimulation, additional mechanisms can restrain active transcription and maintain 
quiescence. Finally, numerous mechanisms mediate the resolution of the inflammatory 
response, including mechanisms that remove transcription factors from inflammatory 
gene promoters (termed transrepression) (for review see 97–99). It is noteworthy that 
Phf15 is involved in the regulation of several of these. 
Perhaps most interestingly, global transcriptional changes after deletion of Phf15 
in mouse microglia closely mimicked recently published aged microglial inflammatory 
phenotypes 153–155. Specifically, microglia of aged mice (18-24 months of age) increase 
expression of type I interferon (IFN-I) responsive genes, upregulating a very similar set 
of genes to our Phf15 knockout microglia under basal conditions. This suggests that 
Phf15 could function as a regulatory checkpoint, restraining the transition from 
homeostatic towards the chronic, proinflammatory, IFN-I responsive state seen in 
microglia during aging. 
Additionally, my work also explored whether factors that are known contributors 
to aging-induced inflammation (inflammaging), for example a high fat diet (HFD) and 
resulting obesity or cellular senescence might contribute to brain inflammation and 
cognitive dysfunction via inhibition of microglial Phf15. Although I found that expression 
of Interleukin-6 (Il-6), a classic marker of the senescence-associated secretory 
phenotype (SASP) 51,52 was decreased in hippocampus—an area that mediates various 
memory-related processes—of aged (27 month old) of STING-deficient mice, this did 
not translate into improved working memory function nor differences in Phf15 levels in 
the brain. Thus, expression of SASP-related inflammatory factors by the cGAS-STING 
pathway might not proceed via inhibition of Phf15. Similarly, prolonged HFD treatment 
and obesity did not affect working memory or levels of Phf15 in the mouse brain, 
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suggesting that brain inflammation resulting from a HFD or obesity is not a result of 
decreased levels of Phf15. 
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